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 Acute kidney injury (AKI) is a serious disorder for which there are limited clinical treatments. 
The Hukriede lab utilizes zebrafish as a screening model to identify small molecules that 
promote expansion of renal progenitor cells (RPCs) in the embryo, with the hypothesis that these 
compounds might also be effective AKI therapeutics by enhancing innate renal regenerative 
processes. This approach identified 4-(phenylthio)butanoic acid (PTBA), a novel class of histone 
deacetylase inhibitors (HDACi) that promotes RPC proliferation in zebrafish embryos by 
stimulating retinoic acid (RA) signaling. To evaluate the therapeutic potential of PTBA-class 
HDACi, we used a nephrotoxic model of gentamicin-induced AKI in zebrafish larvae that 
demonstrates the same hallmarks of renal injury and regeneration as the mammalian kidney. In 
this model, we show that m4PTB, the esterified version of PTBA, enhances post-AKI recovery 
by increasing dedifferentiation and proliferation of renal tubular epithelial cells (RTECs). To 
evaluate whether RA signaling also mediates m4PTB’s effects in this AKI model, we used 
Tg(12XRARE:EGFP) larvae to show that RA signaling increases rapidly after AKI, and that this 
response is critical for RTEC-dependent regeneration. Finally, we show that although m4PTB 
does not directly stimulate RA signaling in zebrafish larvae, blocking the RA pathway abrogates 
m4PTB’s effects on RTEC proliferation.  These studies indicate that enhanced AKI recovery 
following m4PTB treatment requires intact RA signaling, and provide mechanistic insight into 
the signaling pathways involved in kidney regeneration post-AKI. Given the significant 
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healthcare burden posed by AKI, these are critical initial steps in order to improve the treatment 
options available to patients. 
 
 
 
 
 v 
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1.0  INTRODUCTION 
1.1 DEVELOPMENT AND FUNCTION OF THE VERTEBRATE KIDNEY 
1.1.1 Overview of vertebrate kidney development  
Three kidney structures form successively during embryonic development: the pronephros, 
mesonephros, and metanephros. The pronephros, the simplest of these structures, is 
nonfunctional in mammals but functions as the larval kidney of fish and amphibians1, 2. The 
mesonephros serves as the embryonic kidney of mammals and the mature kidney of fish and 
amphibians1, 2. Although transient, these structures are critical for proper development of the 
metanephric kidney, which is the adult kidney of mammals, birds, and reptiles2. 
In mammals, the kidney arises from the primary nephric duct (Wolffian duct), a set of 
bilateral epithelial tubes derived from Lhx1/Pax2/Pax8-positive cells of the intermediate 
mesoderm3, 4 (Figure 1A). As the nephric duct grows caudally in the embryo, a network of 
tubules develops from the surrounding mesenchyme1. The rostral tubes of this network are 
rudimentary and comprise the pronephros, whereas the caudal tubes are more defined and 
comprise the mesonephros1, 2 (Figure 1B).  
The metanephric kidney develops at the caudal end of the nephric duct, where an 
outgrowth of epithelial cells forms the ureteric bud. Interactions between cells of the ureteric bud 
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and surrounding metanephric mesenchyme governed by Ret/Gdnf signaling induce rounds of 
ureteric bud branching, which ultimately determines the number of nephrons, the functional units 
of the kidney5-8. Collections of Six2/Cited1-positive metanephric mesenchyme cells condense at 
the tips of the branching ureteric bud, undergo mesenchymal-to-epithelial transition, and form 
renal vesicles. The renal vesicle then forms the comma-shaped body, followed by the s-shaped 
body (Figure 1C). These final structures form the nephron and are patterned such that the 
proximal end forms the glomerulus, and the distal end forms the connecting tubule, which 
connects to the ureteric bud-derived collecting duct (Figure 1D). Foxd1-positive metanephric 
mesenchyme gives rise to the cortical renal stroma, and Flk1-positive cells contribute to the renal 
vasculature9. Nephron formation concludes by gestational week 36 in humans and continues 
through 10 days after birth in mice10.  
 
 2 
 Figure 1: Schematic of mammalian embryonic kidney development. 
(A) Specification of the kidney field from intermediate mesoderm. (B) Formation of the pronephros and 
mesonephros, and budding of the ureteric bud from the Wolffian duct. (C) Iterative branching of the ureteric bud 
and early development of nephrons from renal vesicles. (D) Depiction of mature nephron segments: proximal 
convoluted tubule (PCT), proximal straight tubule (PST), descending and ascending thin limb (DTL, ATL), thick 
ascending limb (TAL), distal convoluted (DC), connecting tubule (CNT), collecting duct (CD). 
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Analogous to mammalian renal development, the kidney of lower vertebrates including 
zebrafish is derived from a population of pax2a/pax8/lhx1a-positive renal progenitor cells 
(RPCs) in the intermediate mesoderm (Figure 1A)2, 11. These progenitors undergo mesenchymal-
to-epithelial transition to form the pronephros (Figure 2A), which consists of two glomeruli 
fused at the midline located between the neural tube and spinal cord, and two tubules located 
above the yolk2, 11. RPCs are patterned such that anterior cells give rise to proximal nephron 
segments and posterior cells give rise to distal segments (Figure 2B)12. Epithelialization of the 
pronephros is complete by 24 hours post fertilization (hpf), and the glomerulus is fully 
vascularized by 4 days post fertilization (dpf)2. Unlike in mammals, the pronephros functions as 
the larval and juvenile kidney in zebrafish until formation of the mesonephric kidney, which 
begins at 11 dpf13. Developmental studies in animal models including zebrafish embryos have 
been instrumental in advancing our understanding of the cellular and molecular events that 
control kidney organogenesis1, 8-10, 14. 
 
Figure 2: Schematic of pronephric kidney development in zebrafish. 
(A) RPC progenitors in the embryo define the pronephros. (B) The mature pronephros consists of two glomeruli (G) 
fused at the midline, and two bilateral nephrons patterned into distinct segments: neck (N), proximal convoluted 
tubule (PCT), proximal straight tubule (PST), distal early (DE), corpuscle of Stannius (CS), distal late (DL), and 
pronephric duct (PD). These segments terminate at the cloaca (C). 
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1.1.2 Kidney structure and function 
The kidney performs several critical functions. These include blood filtration to remove 
metabolic waste, regulation of fluid and electrolyte balance, and maintenance of bone density. 
Accomplishing these functions requires the coordination of 26 cell types comprising the 
metanephric kidney, which are organized into a sophisticated set of vascularized nephron 
filtering units that drain into a collecting system for urine excretion15. Nephrons consist of a 
glomerulus, the location of blood filtration, and an epithelial tubule that alters filtrate content. 
The tubule is divided into distinct segments characterized by unique expression profiles of 
transport proteins that determine function. In general, proximal segments are responsible for 
fluid reabsorption from the filtrate, whereas distal segments and collecting duct fine-tune the 
composition of the filtrate. Each human kidney contains on average 900,000 nephrons, with 
greater than 10-fold variation existing in the adult population16. Low nephron number is 
associated with both renal and cardiovascular disease16, 17, pointing to the importance of 
understanding the mechanisms of kidney development, injury, and repair. 
1.2 ACUTE KIDNEY INJURY 
1.2.1 Definition and epidemiology  
Acute kidney injury (AKI) is the rapid decline in renal function as defined by changes in serum 
creatinine, glomerular filtration rate (GFR), and urine output18, 19. AKI is common, occurring in 
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3-20% of hospitalized patients20, 21 and in 11-67% of ICU patients22-25, with rates continuing to 
rise26. Rather than a single condition, AKI represents a spectrum of diseases, with increased 
severity correlating with worsened outcome and higher mortality22, 27-29. Ultimately, AKI 
accounts for at least $10 billion in US healthcare costs28 and results in 2 million deaths annually 
worldwide30. 
1.2.2 Pathophysiology 
Leading causes of AKI include sepsis, heart failure, major surgery, and nephrotoxins29-31. In 
reality, the etiology is generally multifactorial and involves combinations of these factors30. 
Since renal biopsy is rarely indicated in AKI patients, the mechanisms underlying 
pathophysiology have been largely defined using rodent animal models32. Perhaps the most well-
characterized model is ischemia reperfusion AKI (IR-AKI), in which investigators temporarily 
clamp the renal artery resulting in organ ischemia. Although not a perfect model, especially in 
recapitulating aspects of sepsis-induced AKI30, 33, 34, ischemia is an important component of AKI 
regardless of initial insult35. Given the scarcity of human kidney tissue, the IR-AKI model has 
been pivotal in advancing our understanding of AKI pathophysiology in humans. These studies 
have identified key players during AKI events that interact in three main compartments: the 
tubular epithelium, vascular endothelium, and cells of the immune system. These components 
are described individually below. 
1.2.2.1 Renal tubular epithelial component 
In IR-AKI, kidney hypoperfusion triggers endothelial vasoconstriction, which exacerbates local 
ischemia and ultimately depletes ATP in renal tubular epithelial cells (RTECs)36-38. Due to a high 
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metabolic workload and location in the kidney, epithelial cells in the proximal tubule (PT) are 
particularly susceptible to ischemic injury, but distal tubular cells are also affected39. Epithelial 
damage is manifested by loss of the apical brush border, disrupted apical-basal cell polarity, and 
weakened cellular junctions35, 37. Severely injured cells undergo cell death, with various 
populations exhibiting autophagy, apoptosis, or necrosis40-43, leaving bare patches of basement 
membrane. These changes result in sloughing of cellular debris and contribute to obstruction of 
the tubular lumen, accumulation of fluid in the interstitial space, and activation of immune cells37 
(Figure 3A-B). Blocking apoptotic cell death by inhibiting either p53 or caspase signaling has 
been shown to be renoprotective and improves outcome after AKI44-47.  
Since nephrogenesis halts shortly after birth in mammals48, 49, recovery after AKI 
depends on the repair of damaged tubules. Injured RTECs dedifferentiate and proliferate to 
repopulate areas of lost cells50 (Figure 3C). During these processes, cells reactivate 
developmentally-expressed genes and pathways14, 51, including vimentin52, Pax253, Lhx154, and 
Wnt signaling55, 56. These mechanisms comprise the kidney’s post-injury regenerative potential.  
In contrast to proliferation-mediated repair, maladaptive epithelial responses have also 
been observed after injury. A proportion of RTECs that attempt to proliferate do not successfully 
complete the cell cycle and arrest in G2/M57. These arrested cells activate c-Jun N-terminal 
kinase (JNK) signaling, resulting in the secretion of profibrotic factors including transforming 
growth factor beta 1 (TGF-β1) and connective tissue growth factor (CTGF)57 (Figure 3D). These 
events have negative consequences for recovery. First, cell cycle arrest depletes the proliferative 
pool that replaces dead cells. Second, RTEC secretion of profibrotic factors activates fibroblasts 
and contributes to tissue scarring. What triggers these maladaptive responses remains poorly 
understood and actively investigated. 
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 Figure 3: Cellular hallmarks of AKI. 
(A) Healthy tubular epithelial cells, with intact cellular junctions and apical-basal polarity. (B) Characteristic 
cellular changes induced by AKI include loss of brush border and apical-basal polarity, sloughing of cellular debris, 
and influx of immune cells. (C) Epithelial proliferation response post-injury. (D) Some injured epithelial cells arrest 
in G2/M and secrete profibrotic factors, leading to scar tissue formation and maladaptive repair. 
 
1.2.2.2 Vascular component 
The vasculature performs several important functions to ensure adequate blood flow. Endothelial 
cells regulate vessel tone, maintain proper permeability, block cellular adhesion, and support 
anti-coagulation. AKI impairs all of these functions, and compared to the tubular epithelium, the 
renal vascular endothelium demonstrates minimal regeneration38. 
AKI rapidly disrupts endothelial cell-cell junctions, resulting in capillary leak within 2 
hours post-injury58. Injured endothelial cells also upregulate cell adhesion molecules including 
intercellular adhesion molecule 1 (ICAM-1) and E/P-selectins38, 59-61. Combined, these changes 
facilitate the adhesion and transmigration of leukocytes. Finally, injured endothelial cells 
decrease production of anti-coagulation proteins, activating the clotting response38. The net result 
of these changes is the occlusion of small vessels, which further exacerbates ischemia and 
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cellular injury. Ultimately, many of these small vessels are lost (“vascular dropout”), 
contributing to long-term hypoxia and predisposing the kidney to future injury. Strategies to 
preserve the renal endothelium have been shown to be beneficial in animal AKI models and 
include increasing vasodilation, enhancing anti-coagulation, and blocking leukocyte adhesion37, 
38, 62. These studies, however, provide only renoprotective benefits and may not be viable post-
injury treatment options. 
Additionally, the injured vascular system may contribute to renal fibrosis. In the 
uninjured kidney, pericytes surround and communicate with endothelial cells to regulate barrier 
function and vascular tone. Several studies suggest that during AKI, pericytes detach and 
differentiate into activated interstitial myofibroblasts. These cells generate fibrotic tissue around 
dying tubules63-66. Blocking pericyte detachment decreased fibrosis in a mouse unilateral ureteral 
obstruction (UUO) model, providing further evidence that pericyte activation results in fibrosis67.  
1.2.2.3 Inflammatory component  
In the healthy kidney, the immune cell population is sparse and consists primarily of resident 
dendritic cells and macrophages that help maintain homeostasis68, 69. Upon injury, RTECs 
increase expression of the toll-like receptors TLR2 and TLR4 and produce a milieu of pro-
inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and TGF-β1, which 
attract leukocytes to the kidney70, 71. As described above, injured endothelial cells are also key 
participants in leukocyte infiltration. 
 The innate immune response is activated rapidly, with neutrophils arriving within 30 
minutes of IR-AKI injury72. These phagocytes clear pathogens and cellular debris, secrete tissue-
remodeling factors, and attract macrophages. The role of neutrophils in AKI is up for debate. 
Some groups demonstrated amelioration of injury and preservation of endothelial barrier 
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function when neutrophil transmigration was inhibited59, 73, while other studies reported no 
effect74, 75. These findings are not surprising given the diversity of neutrophil functions, and 
warrant careful studies that evaluate timing and depletion efficiency in the context of a particular 
model.  
 Heterogeneous macrophage populations have been identified that participate in both 
tissue injury and repair76, 77. Early in the course of injury, inducible nitric oxide synthase (iNOS)-
positive M1-type macrophages infiltrate the kidney and perpetuate damage and epithelial 
apoptosis by secreting pro-inflammatory cytokines and producing reactive oxygen species 
(ROS)77. Depletion of macrophages during this early phase decreases tubular cell death and 
prevents renal functional impairment78, 79. Between 2 and 3 days after injury, environmental 
cues, for example phagocytosis of apoptotic cells, trigger suppression of M1 macrophages and 
promote M2 polarization77, 78. M2 macrophages express arginase 1 and mannose receptor (MR) 
and are generally considered to promote tissue repair. These repair phase macrophages 
proliferate in situ80, protect RTECs from apoptosis, and promote cell cycle progression56, 81, 82. 
Several studies have demonstrated the importance of this phenotype switch. Failure to suppress 
the M1 phenotype leads to poor long-term outcome with increased fibrosis83. Suppressing M2 
proliferation or depleting macrophages late during repair when these cells predominate increases 
injury, impairs functional recovery, decreases epithelial proliferation, and increases fibrosis56, 78, 
80, 84. Directly administering M2-polarized cells is renoprotective during AKI85. 
1.2.3 Treatment and outcome 
Effective AKI treatment relies on early diagnosis and identification of the underlying cause. 
There are currently no targeted clinical treatments that accelerate renal recovery or decrease 
 10 
fibrosis when administered after injury. Treatment is supportive and includes discontinuation of 
nephrotoxic therapies, fluid resuscitation, and renal replacement therapy30. Although the timing 
and intensity of these treatments remains controversial86-88, it is generally accepted that early 
intervention leads to higher patient survival89. 
Severe AKI that requires renal replacement therapy carries the highest mortality rate of 
up to 60%29, 90, but even mild AKI is associated with increased risk of death91, 92. It was 
previously believed that renal function returned to baseline after resolution of an AKI episode93, 
94, but accumulating evidence points to AKI as a significant risk factor for chronic kidney 
disease95, 96.  
Several mechanisms have been proposed to mediate the transition from AKI to chronic 
kidney disease. First, nephron loss during AKI exposes surviving nephrons to increased 
workload and increased cellular stress, thus decreasing future regenerative capability96, 97. 
Second, severe AKI causes cell cycle arrest in G2/M phases and subsequent production of 
profibrotic factors that promote scar tissue formation57. Third, it has been shown that persistence 
of the inflammatory response after AKI, in particular M1 macrophages, exacerbates fibrosis83, 98. 
Finally, endothelial damage and vascular dropout during AKI lead to hypoxia, resulting in 
further inflammation and fibrosis66, 96, 97, 99. Direct causality has not yet been established100, but 
these factors may explain how cellular damage that occurs during AKI could lead to fibrosis and 
long-term renal impairment. 
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1.3 HISTONE DEACETYLASE INHIBITORS AND KIDNEY DISEASE 
1.3.1 Overview 
Although initially developed as chemotherapeutic agents, the discovery that histone deacetylase 
inhibitors (HDACi) can reduce fibrosis and attenuate injury-mediated damage in kidney disease 
models has opened the possibility of utilizing HDACi as therapeutics for AKI. Since histone 
deacetylases (HDACs) play multiple roles during both kidney organogenesis101 and the 
pathogenesis of kidney disease102, the continued development of isoform-selective HDACi has 
provided necessary tools to study the individual roles that HDACs play during these processes.  
1.3.2 HDAC function 
Acetylation and deacetylation of nucleosomal histone proteins serves as a post-translation 
modification that regulates transcriptional activity. This mechanism involves the interplay 
between the activity of two enzyme classes: (1) histone acetyltransferases (HATs), which 
promote an open chromatin configuration and transcriptional activation, and (2) HDACs, which 
generally promote chromatin condensation and transcriptional repression. Specifically, most 
HDACs remove acetyl groups from the ε-amino moiety of lysine residues located on N-terminal 
histone tails. This leaves the histone with a net positive charge, strengthening its electrostatic 
interaction with the DNA phosphate backbone resulting in transcriptional repression of 
associated genes.   
As members of large multiprotein complexes, HDACs also target many non-histone 
proteins103 and, in some instances, participate directly in gene activation104, 105. For example, 
 12 
HDACs positively regulate the oncogene c-Jun as well as the anti-apoptotic gene B-cell 
lymphoma 2 (Bcl-2)105. Additionally, it has been demonstrated that HDACs are required for 
interferon-induced gene expression, which is critical for an antiviral immunological response106. 
Therefore, the function of HDACs, either as corepressors or coactivators, appears to be context-
dependent. 
1.3.3 HDAC classification  
To date, 18 mammalian HDAC proteins have been identified, and they are divided into four 
classes based on similarity to yeast orthologs107. Class I, II, and IV enzymes depend on zinc for 
catalytic activity and contain a highly conserved deacetylase domain102, 108. Class III enzymes 
(sirtuins) are structurally distinct from the other HDAC classes since the catalytic activity of 
these enzymes depends on NAD+ rather than zinc and histones are not their primary substrate102, 
108. Class I is comprised of HDACs 1, 2, 3, and 8. Class II is subdivided into class IIa, containing 
HDACs 4, 5, 7, and 9, and class IIb which contains HDACs 6 and 10. HDAC 11 is the sole 
member of Class IV because its catalytic domain resembles the active sites of both class I and 
class II enzymes108. 
Understanding HDAC substrate specificity, as well as identifying strategies for 
developing novel isoform-selective HDACi, depends on thoroughly distinguishing between and 
within HDAC classes102, 108, 109. Class I HDACs are expressed ubiquitously, are localized to the 
nucleus, and interact with corepressor complexes to exert their function. HDAC1 and HDAC2 
are recruited to the nucleosome remodeling and deacetylation (NuRD), corepressor for RE1 
silencing transcription factor (Co-REST), and Sin3 corepressor complexes. HDAC3 is most 
often recruited to the silencing mediator for retinoid and thyroid receptors/nuclear receptor 
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corepressor (SMRT/N-CoR) complex110. Additionally, the active site of HDAC3 contains a 
unique tyrosine residue (Tyr198) not present in the active sites of other HDACs in its class, 
which may contribute to the substrate specificity of HDAC3111. HDAC8 does not appear to be 
recruited to corepressor complexes and is the only class I HDAC with intrinsic enzymatic 
activity111. 
In contrast to class I, class II HDACs are thought to have tissue-specific roles, and are 
expressed in both the cytoplasm and the nucleus112. Class IIa enzymes contain a mutation in the 
catalytic site, resulting in a 1,000-fold reduction in activity108. Therefore alternative mechanisms, 
such as the recruitment of class I HDACs108 or the interaction with corepressor complexes such 
as SMRT/N-CoR110, 113, may be required to achieve activity. Additionally, it has been proposed 
that this class of HDACs might act as “receptors” rather than enzymes, since they often bind 
acetylated lysine residues without performing the deacetylation reaction114. While little is known 
about the function of the class IIb member HDAC10, the structure of HDAC6 is unique and 
consists of two catalytic domains and a zinc finger. Although α-tubulin was thought to be its 
primary target115, increasing evidence suggests that HDAC6 also plays key functions during 
cellular stress. By binding ubiquitin, HDAC6 senses the accumulation of misfolded proteins and 
subsequently activates the heat shock protein response116-118.   
1.3.4 Available HDAC inhibitors 
HDACi targeting class I and II HDACs generally follow a classic warhead-linker-cap structure 
(Figure 4). The warhead, or chelator, binds zinc in the HDAC catalytic site, rendering the 
enzyme inactive. The linker is a carbon chain that connects the warhead and cap and spans the 
length of the HDAC pocket. The cap, or surface-binding domain, interacts with residues on the 
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surface of the HDAC enzyme and contributes to isoform specificity of the inhibitor 114. There are 
at least four categories of HDACi that adhere to this structure: short chain fatty acids, 
hydroxamic acids, aminobenzamides, and cyclic peptides. The short chain fatty acids are 
carboxylic acids that include valproic acid (VPA), butyric acid, phenylbutyrate (PBA), and 4-
(phenylthio)butanoic acid (PTBA). These inhibitors are relatively weak and display some class I 
specificity. The hydroxamic acids are more broad-spectrum inhibitors capable of inhibiting class 
I and II HDACs, and include trichostatin A (TSA), suberoylanilide hydroxamic acid (SAHA), 
LBH-589, LAQ-824, and PXD-101. Aminobenzamides are class I-selective and include SNDX-
275, MGCD0103, and MS-275. Finally, there are several cyclic peptides, such as depsipeptide 
(romidepsin/FK-228) and apicidin, which appear moderately selective for class I HDACs102, 119. 
Although originally isolated as natural compounds, several synthetic analogues have now been 
created120, 121.  
Due to their pro-differentiation, anti-proliferative effects, HDACi have generated 
excitement in the cancer field as novel chemotherapeutic agents122, 123. Traditionally, PBA has 
been used to treat disorders of the urea cycle due to its nitrogen scavenging effects since the 
1990s124. SAHA (vorinostat) was the first FDA-approved HDACi for the treatment of refractory 
cutaneous T-cell lymphoma119. In addition, about a dozen other compounds have entered clinical 
trials114 and in 2009, the FDA also approved FK-228 (romidepsin), for treatment of cutaneous T-
cell lymphoma125. Currently, vorinostat and romidepsin are the only two FDA-approved HDACi. 
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 Figure 4: Characteristic design of HDAC inhibitors. 
The general structure of HDACi can be broken into three regions, each with a specific function: cap, linker, 
and warhead. Modifications can be introduced at each portion of the moiety, contributing to structural 
diversity126. 
 
1.3.5 Toxicities and limitations of HDACi therapy 
From a global perspective, patients tolerate HDACi therapy quite well, and the maximum 
tolerated dose has yet to be reached in some regimens123. Common side effects of vorinostat, 
romidepsin, and MS-275 include fatigue, nausea, and vomiting, although these are reversible 
upon treatment withdrawal123, 127. More worrisome, however, are the cardiac and immunologic 
effects, such as QT prolongation, thrombocytopenia, and/or myelosuppression, following 
HDACi treatment. Specifically, QT prolongation was observed during clinical trials with 
romidepsin, although confounding factors were also identified in specific patient populations125. 
Additionally, VPA is a teratogen known to cause neural tube and other birth defects128. Although 
one study determined that TSA administered to pregnant mice did not harm either the mothers or 
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the pups129, further studies are warranted to characterize the specific toxicity profiles associated 
with various HDACi. 
1.3.6 HDACi attenuate fibrosis and inflammation in kidney disease 
As described previously, the pathogenesis of many kidney diseases is characterized by 
dysregulation of cellular proliferation and infiltration by inflammatory cells, leading to 
irreversible fibrosis. While therapeutic options in the clinic are limited, HDACi are promising 
treatments for targeting both the profibrotic and inflammatory pathogenic aspects of kidney 
disease across many injury models130, 131. These studies are summarized in Figure 5132-139. 
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Figure 5: Summary of HDACi therapies used in renal disease models. 
Several HDACi have been found to attenuate fibrotic, inflammatory, and proliferative features of renal disease in 
mammalian models. Studies are organized by location of damage in the nephron in the injury model126. 
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To ameliorate renal fibrosis, researchers have focused their efforts on elucidating the 
mechanisms of TGF-β signaling. TSA treatment prevented TGF-β1-dependent responses in 
cultured human RTECs140. Cells treated with TSA still demonstrated Smad protein 
phosphorylation, which relays TGF-β1 signaling to the nucleus, indicating that TSA blocks the 
defects of TGF-β1 downstream of these factors. Co-treatment of human RTECs with TGF-β1 
and TSA prevented TGF-β-induced apoptosis by blocking caspase protein cleavage (also 
observed in an in vivo model138). This effect was mediated by inhibiting extracellular signal-
regulated kinase (ERK) activation. This latter finding is notable since recent studies have shown 
that epidermal growth factor receptor (EGFR) is required for sustained TGF-β-dependent fibrosis 
in a mouse model of angiotensin II-induced renal fibrosis141. Thus, this work proposes a dual 
therapeutic role for HDAC inhibition in preventing tubular interstitial fibrosis: (1) suppressing 
the profibrotic effects of TGF-β1, and (2) mitigating renal tubular atrophy by protecting against 
tubular epithelial cell apoptosis. 
Additional mechanisms have been proposed for attenuating tubular damage-mediated 
fibrosis through HDAC inhibition. In a mouse model of UUO, Pang et al. observed a decrease in 
fibrotic markers in TSA-treated kidneys138. This was associated with decreased levels of 
phosphorylated signal transducer and activator of transcription 3 (STAT3). Since STAT3 has 
been implicated in the regulation of tubulointerstitial fibrosis following UUO142 and is a known 
HDAC target, these findings suggest HDACi may also decrease renal fibrosis by decreasing 
STAT3 signaling in this model of chronic kidney disease. Thus, HDACi are likely contributing 
in multiple ways to exert antifibrotic effects. 
HDACi have also been implicated in the prevention of inflammatory infiltration after 
renal damage. Following UUO, there is an increase in both HDAC1 and HDAC2 in the tubular 
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epithelium. While treatment with TSA decreased fibrosis scores, it also decreased macrophage 
infiltration and expression of colony-stimulating factor 1 (Csf1), a secreted cytokine that 
promotes proliferation and survival of monocyte/macrophages.  Similarly, TSA and VPA were 
able to attenuate TNF-induced Csf1 expression in cultured rat RTECs143. Work by another group 
demonstrated that treatment with FR276457, a hydroxamic acid derivative that inhibits both 
class I and II HDACs, resulted in decreased monocyte chemotactic protein 1 (MCP1) levels, a 
chemotactic cytokine that normally attracts macrophages to the kidney shortly after UUO139.  
However, the role of macrophages in acute and chronic kidney injury is complex and involves 
both the detrimental effects of early, inflammatory M1 macrophages, and late, anti-inflammatory 
M2 macrophages that also enhance epithelial regenerative responses68. Therefore HDACi may 
decrease pro-inflammatory M1 macrophages early, and/or promote expansion of anti-
inflammatory and pro-regenerative M2 macrophages later in the course of disease.  
1.3.7 HDACi in acute kidney injury 
In addition to antifibrotic and anti-inflammatory effects, there is also evidence that epigenetic 
modulation through HDAC inhibition can promote regeneration after tissue injury by 
reactivating the expression of signaling machinery normally required during kidney 
organogenesis. In particular, bone morphogenic protein 7 (BMP7) is detected in the developing 
mammalian kidney and reactivated after renal ischemia54. Further, exogenous BMP7 treatment is 
therapeutic in rodent kidney injury models144-146. Several groups have determined that this 
reactivation may be HDAC dependent.    
Marumo et al.132 observed that exposure to transient renal ischemia resulted in histone 
hypoacetylation in mouse PT epithelial cells.  This led them to investigate whether HDACs 
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played a role in modulating the kidney’s response to ischemic injury. Recovery after reperfusion 
in vitro was associated specifically with decreased levels of HDAC5, and knockdown of HDACs 
1, 2, or 5 induced expression of Bmp7. In vivo, fewer HDAC5-positive cells were observed in 
the PT after reperfusion, which correlated with histone hyperacetylation and induction of BMP7.   
The role of HDACs and BMP7 was examined further in a mouse model of septic AKI147. 
In this study, increased Hdac2 and Hdac5 and decreased Bmp7 expression was observed in the 
kidney after cecal ligation and puncture. However, TSA treatment before surgery prevented 
Hdac2 and Hdac5 induction, and increased Bmp7. These changes were associated with enhanced 
functional recovery and decreased tubular damage, possibly through mitigating inflammation. 
Accordingly, TSA pre-treatment decreased Tnfα and Mcp1 expression levels in the kidney. 
Therefore, the induction of BMP7 through HDAC2 or HDAC5 inhibition may prevent renal 
injury through effects on the inflammatory response. 
Finally, Imai et al. showed that TSA treatment prevented proteinuria and blood urea 
nitrogen (BUN) elevation in nephrotoxic nephritis (NTN) mice135. This global attenuation of 
renal injury was associated with activation of Bmp7 expression in an uncharacterized side 
population of cells identified by flow cytometry.  Although rather controversial, some believe 
this side population may constitute a population of intrarenal stem cells148, 149. Since TSA 
treatment did not increase Bmp7 expression in other renal cells, this population may serve as a 
source of BMP7 to promote renal regeneration. This suggests that pharmaceutical HDACi 
therapy may have the potential to stimulate the BMP pathway – or other developmental 
pathways – and promote regeneration, thus ameliorating kidney injury. Importantly, these 
changes in histone acetylation status and gene expression occur during the recovery phase after 
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reperfusion, implying that HDACi treatment – in contrast to the renoprotective strategies 
discussed above – may be a useful therapy after injury has occurred in the hospital setting. 
1.4 RETINOIC ACID SIGNALING 
1.4.1 Pathway overview 
Vitamin A is essential for life and has been studied for almost 100 years150. Cells metabolize 
vitamin A to several retinoids including all-trans retinoic acid (ATRA)151, which is the 
metabolite largely responsible for influencing expression of over 500 genes that regulate 
embryonic development, immunology, stem cell differentiation, and cancer biology152.  
 Retinoic acid (RA) levels are regulated by the spatiotemporal expression of enzymes 
responsible for its synthesis and degradation. Vitamin A enters the cell in its alcohol form as 
retinol, and is oxidized to retinaldehyde by alcohol/retinol dehydrogenase (ADH/RDH) enzymes, 
and subsequently to RA by retinaldehyde dehydrogenase (RALDH) enzymes151, 153. In free acid 
form, RA can diffuse to nearby cells signaling in a paracrine fashion, where it is ultimately 
degraded by members of the cytochrome P450 family of enzymes, CYP26s151, 153, 154. Together, 
these enzyme families establish a gradient of RA to exert tight control over signaling within 
specific tissues, which is critical since both RA deficiency and excess are detrimental to 
development and health155, 156. 
Intracellular RA binds to nuclear retinoic acid receptors (RARs), which heterodimerize 
with retinoid X receptors (RXRs)157. In mammals, there are 3 RARs (α, β, and γ) and 3 RXRs (α, 
β, and γ)158. These receptors pairs are transcriptional complexes that bind directly to retinoic acid 
 22 
response elements (RAREs), consensus DNA sequence repeats located upstream of target 
genes153. Since direct measurement of RA levels is technically difficult, the generation of 
transgenic animals that utilize RAREs to drive reporter gene expression has provided the 
scientific community with critical tools to study RA signaling dynamics159-162.  
In the absence of RA, gene expression is inhibited by RAR-RXR recruitment of 
corepressor complexes (SMRT/N-CoR), which include HDAC proteins153, 163. RA binding 
induces a conformation change, resulting in the exchange of corepressors for coactivators 
including HATs that open chromatin for target gene transcription153, 163. Generally, RA binding 
results in the activation of gene transcription; however, in rare cases ligand binding induces 
HDAC recruitment and gene silencing164, 165. 
1.4.2 Role in renal development 
RA signaling plays several important roles during brain, heart, liver, lung, pancreas, limb, and 
kidney formation166-168. The requirement for proper development has been established by genetic 
deletions of pathway components in rodent models. These studies demonstrate that loss of RARs 
during embryogenesis results in an array of developmental defects, and deletion of RALDH2 
enzyme alone is embryonic lethal156, 168.  
RA is important for the specification and patterning of the pronephric kidney field. 
During gastrulation, inhibition of RA signaling ablates the Lhx1-positive kidney progenitor cell 
population and prevents tubule formation in Xenopus embryos169. Loss of RA signaling also 
decreases expression of pronephric kidney markers in mouse embryos169. Conversely, exogenous 
RA treatment expands the kidney field in Xenopus and induces embryonic stem cells to express 
intermediate mesoderm markers169, 170. These findings suggest that RA is critical for intermediate 
 23 
mesoderm specification. Studies in zebrafish have demonstrated that RA signaling is also 
important in determining proximal-distal patterning of the pronephros. During somitogenesis, 
caudal transcription factors (cdx) establish clear expression domains of raldh and cyp26 enzymes 
in the paraxial mesoderm, generating a gradient of RA availability171. Nephron progenitors 
exposed to higher RA levels become proximal tubule segments, whereas those exposed to lower 
RA levels become distal tubule segments171. Disruption of either cdx expression or RA signaling 
impairs segment identity171, 172.  
Finally, RA signaling induces growth and branching of the ureteric bud during 
metanephric kidney development173. RA signaling in the renal stroma induces Ret expression in 
ureteric bud cells, which is critical for ureteric bud branching and nephron formation6, 7. 
Consequently, loss of RA signaling during fetal development, induced by vitamin A deficiency 
or deletion of RARs, causes severe kidney malformations174, 175. Even mild vitamin A reduction 
results in decreased nephron number at birth in rats176. In humans, low maternal vitamin A intake 
during pregnancy is associated with decreased renal volume at birth177, and this decreased 
nephron endowment is implicated in cardiovascular and renal disease in adult life16, 17.   
1.4.3 Role in renal disease and regeneration 
RA mediates regenerative processes across many organ systems, often by reactivating 
developmental mechanisms that orchestrate organogenesis178, 179. Classic studies of limb 
epimorphic regeneration in amphibians demonstrate that exogenous RA results in the super-
regeneration of extra, mispatterned limbs178. Later studies in zebrafish demonstrated that RA 
induces the dedifferentiation and proliferation of mesenchymal blastema cells by modulating 
fibroblast growth factor (FGF) and Wnt signaling, thus coordinating fin regeneration180, 181. In 
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other organ systems, RA promotes neuron growth and decreases macrophage infiltration after 
axon damage182, ameliorates emphysema in rats potentially by stimulating alveolar epithelial 
proliferation179, and regulates cardiomyoctye proliferation after cardiac injury in zebrafish183. In 
these models, RA provides pro-proliferative and anti-inflammatory signals that positively affect 
tissue regeneration179. It is important to point out that these effects are context-dependent, and in 
the cancer field, retinoids are commonly used as chemotherapeutic agents that arrest proliferation 
and induce differentiation of tumor cells184, 185.  
In the kidney, retinoids have largely been studied in glomerular diseases, which are 
characterized by podocyte injury and loss that leads to proteinuria and sclerotic lesions186, 187. 
Across several rodent models of glomerular injury, RA treatment decreases proteinuria and 
sclerosis, impairs podocyte proliferation, and preserves glomerular structure and function188-192. 
Recently, two studies provided mechanistic insight into the role of RA in glomerular disease by 
demonstrating that albumin binds and sequesters RA in podocytes, thereby preventing the 
proliferation and differentiation of podocyte progenitor cells193, 194. Thus, proteinuria deprives 
podocyte progenitors of RA, leading to aberrant proliferation and ultimately to podocyte loss and 
sclerosis.  
In addition to effects on podocytes, RA decreases infiltration of macrophages and T cells 
and reduces fibrosis in both glomerular and tubulointerstitial disease models188, 189, 191, 195. These 
findings were correlated with reduced levels of MCP1188, 195. These studies are consistent with 
the anti-inflammatory effects of retinoids described in other disease models and point to the 
promise of retinoid therapy across a variety of renal diseases179, 182. 
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1.4.4 RA signaling and HDACs  
In the classical model of RA signaling described above, RAR-RXR pairs exist in the absence of 
RA ligand bound in corepression complexes containing HDAC enzymes that condense 
chromatin and inhibit gene transcription153, 163. These complexes are well known to contain 
HDAC3, but HDACs 1, 2, 4, 5, and 7 have also been shown to interact110. Thus, HDACi that 
block the activity of these corepressor-bound HDACs may activate RA target genes at 
endogenous RA levels lower than normally required to initiate gene transcription196. 
The link between RA signaling and HDAC inhibition is best characterized in the cancer 
field, which often utilizes combinatorial RA-HDACi chemotherapy to halt proliferation and 
drive differentiation and apoptosis in cancer cells184, 185. Combinatorial therapy is particularly 
potent in the treatment of malignancies that have shown resistance to RA alone197, 198. Data from 
renal cell carcinoma (RCC) cell lines suggest that retinoid-resistance is often due to loss of 
RARβ2 expression199. Treatment with MS-275 (entinostat) results in hyperacetylation of the 
RARβ2 promoter and re-expression of this gene, restoring sensitivity of these lines to retinoids. 
When MS-275 is combined with 13-cis-retinoic acid, there is a significant inhibition of RCC 
tumor growth in mouse xenografts. Similar results have been obtained with TSA and RA200. 
Another possible mechanism involves the reactivation of Caspase-8 with HDAC8 inhibition, 
which then synergizes with RA to promote differentiation of neuroblastoma cancer cells201, 202. 
Combinatorial RA-HDACi has been used in phase I clinical trials for patients with advanced 
solid tumors, including renal malignancies203. Taken together, these studies demonstrate how RA 
and HDACi synergize to influence gene expression as a potent cancer treatment strategy.  
This link has also been shown by the Hukriede lab in the context of renal development. 
Treatment of zebrafish embryos with PTBA, a class I HDACi, expands the kidney field by 
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increasing proliferation of lhx1a-positive RPCs204. Injection of a construct encoding a dominant-
negative RAR prevented kidney field expansion, suggesting that RPC proliferation depends on 
intact RA signaling204. Analogous to the cancer field, this study demonstrates that RA and 
HDACi treatment can also work together during embryonic development. Importantly, RA-
HDACi drives cell cycle arrest and differentiation in cancer cells, but drives proliferation of 
RPCs during renal development, suggesting that the actions of RA and HDACi are context-
dependent. 
1.5 LARVAL ZEBRAFISH AS A MODEL SYSTEM 
1.5.1 General strengths of the zebrafish model system 
The zebrafish (Danio rerio) was pioneered as a model organ system by Dr. George Streisinger at 
the University of Oregon in the 1980s. Thirty years later, zebrafish are currently studied in over 
950 labs worldwide (zfin.org; 6/16/2015). Zebrafish afford key advantages for biomedical 
research, including ease of maintenance, external fertilization and development, large clutch size, 
genetic tractability, and optical clarity during embryogenesis. Several organs in zebrafish possess 
a robust regeneration potential through adulthood, facilitating drug discovery in neural, 
endocrine, renal, and cardiac research. Importantly, the Sanger Institute completed sequencing of 
the entire zebrafish genome in 2013. This work identified zebrafish orthologs for 71% of all 
human genes, and orthologs for 82% of genes associated with human disease205. Thus, the 
zebrafish has become an influential model system to elucidate disease mechanisms and to 
identify new drug targets for these diseases in humans. 
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1.5.2 Zebrafish larvae as an AKI model  
The larval pronephric kidney affords several advantages for AKI studies. First, the structure is 
simple consisting of only two nephrons. Second, segmentation is conserved between zebrafish 
and mammalian nephrons, demonstrating functional similarity12. Third, the response to renal 
injury in the larva involves cellular repair within existing nephrons, whereas injury in the adult 
induces the formation of entire new nephrons206-208. Finally, zebrafish larvae possess an intact 
innate immune system with active, circulating neutrophils and macrophages observed at 3 dpf209. 
Although adaptive immunity does not develop until juvenile stages, zebrafish transgenic lines 
that mark specific leukocyte populations have been instrumental to studying the inflammatory 
component of infection and regeneration209, 210. For these reasons, the larval zebrafish pronephric 
kidney is an apt model to study AKI. 
1.5.3 Zebrafish larvae as a drug discovery model 
Zebrafish embryos are small and develop rapidly, with many organ systems functioning by 2 dpf. 
These characteristics enable the use of zebrafish embryos as a high-throughput tool for drug 
discovery and toxicology screens. Embryos can be arrayed in multi-well plates, treated with 
compound libraries, and examined for effects on health, transgene expression, or other desired 
phenotypes to identify novel drug candidates211. For example in the kidney, automated imaging 
combined with detection algorithms can locate the embryo, map expression domains, and detect 
regional changes in Tg(lhx1a:EGFP) levels212. This assay can be used to identify small 
molecules that expand the RPC field during kidney development212.  
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Prior to this work, a chemical library screen was performed in the Hukriede lab that 
examined the effects of 1990 small molecules on zebrafish embryo development. From this 
screen, the PTBA class of novel HDACi was identified, and was shown to expand the kidney 
field by enhancing RPC proliferation204. These studies led to the main hypothesis of the work 
presented here: since PTBA increases RPC proliferation during kidney development, this class of 
compounds may hold promise as AKI therapeutics by similar signaling mechanisms. 
 
 
Material modified and re-published with permission: 
126*Brilli LL, *Swanhart LM, de Caestecker MP, Hukriede NA. HDAC inhibitors in kidney 
development and disease. Pediatric nephrology. 2013;28(10):1909-21. doi: 
10.1007/s00467-012-2320-8. PubMed PMID: 23052657; PubMed Central PMCID: 
PMC3751322. 
*Denotes equally contributing authors. 
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2.0  CHARACTERIZATION OF THE ACUTE KIDNEY INJURY ENVIRONMENT 
IN ZEBRAFISH LARVAE 
2.1 HYPOTHESIS 
Developing novel treatment strategies for AKI requires both a thorough understanding of the 
pathophysiologic mechanisms, and animal models that reliably recapitulate these complexities. 
Given the strengths of zebrafish as a drug discovery model, and since adult zebrafish generate 
new nephrons throughout life, we decided to develop a model of nephrotoxic AKI in zebrafish 
larvae. Due to the physiological and functional similarities between zebrafish pronephric and 
mammalian metanephric nephrons12, we hypothesized that this AKI model would recapitulate 
many hallmarks of injury and regeneration. 
2.2 RESULTS 
2.2.1 Gentamicin induces renal failure in zebrafish larvae 
We first determined the time course of renal injury in response to gentamicin, an aminoglycoside 
antibiotic that at high doses causes AKI in humans. Renal injury results from the disruption of 
mitochondrial function, which leads to PT cell damage and apoptosis213, 214. Gentamicin was 
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delivered to zebrafish larvae by microinjection into the common cardinal vein at 2.5-3 dpf, 
resulting in edema at 2-3 days post-injection (dpi), consistent with compromised renal function 
as previously shown207. The percentage of edematous and dead larvae at 3 dpi increased with 
increasing injection dose (Figure 6A). Based on these findings, we developed a scoring system 
for gentamicin toxicity. Larvae with no pericardial edema or other phenotypic alterations were 
classified as “normal”; those exhibiting pericardial edema and low mortality rate were designated 
“moderate” larvae; those with generalized edema and higher mortality rate were designated 
“severe” (Figure 6B-E).  To generate a high proportion of moderate/severe AKI, we used a 
working range of 5-8ng gentamicin, and selected surviving fish for subsequent experiments at 2 
or 3 dpi with moderate/severe AKI (referred to as gent-AKI).   
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 Figure 6: Gentamicin injection induces edema and death in zebrafish larvae. 
(A) Gentamicin dose curve. Larvae were injected with increasing doses of gentamicin at 2.5 dpf, and the severity of 
AKI corresponding to injection dose was evaluated by scoring the proportion of larvae that displayed no edema, 
moderate phenotype, severe phenotype, or death at 3 dpi (n=5 experiments, 20-25 larvae/group). (B-E) Appearance 
of zebrafish larvae after gentamicin-induced AKI. Zebrafish larvae at 5 dpf (3 dpi) uninjected (B), injected with 
saline solution (C), or 5-7.5ng gentamicin (gent-AKI) with moderate phenotype displaying pericardial edema (black 
arrow) (D), and severe phenotype displaying both pericardial and general edema (red asterisk) (E). Experiments 
performed by C. Cosentino and L. Brilli Skvarca215. 
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2.2.2 Gentamicin injection induces renal tubular injury 
To visualize pronephric tubular injury caused by gentamicin in zebrafish larvae, we used the 
transgenic line Tg(PT:EGFP), in which enhanced green fluorescence protein (EGFP) is 
expressed in the PT segments and neural crest cells. Compared to uninjured larvae, edematous 
gent-AKI larvae showed distension of the tubular lumen (Figure 7A-B) with epithelial cell 
flattening at 3 dpi (Figure 7C-D). Whereas uninjured larvae displayed few if any apoptotic cells, 
gent-AKI larvae showed increased terminal deoxynucleotidyl transferase dUTP nick end-
labeling (TUNEL) staining in the PT (Figure 7E-F). To assess cell polarity, we performed whole 
mount immunofluorescence for the Na/K ATPase α-subunit (anti-α6F), which is normally 
localized to the basolateral membrane. Na/K ATPase staining was properly distributed along the 
basolateral membrane of PT cells in uninjured larvae but was diffusely distributed throughout the 
cytoplasm in gent-AKI larvae, indicating loss of cell polarity. Gent-AKI larvae also showed 
extrusion of cellular debris into the tubular lumen (Figure 7G-H). Taken together, these data 
show clear similarities between gentamicin-induced pronephric injury in zebrafish larvae and 
mammalian AKI35. (See Figure 31 in Appendix A for general anatomic orientation on transverse 
sections of zebrafish larvae.)  
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 Figure 7: Zebrafish larvae show morphological hallmarks of AKI after gentamicin injection. 
Uninjured larvae (A, C, E, G) or gent-AKI larvae (B, D, F, H) analyzed at 3 dpi. (A-B) Lateral view of Tg(PT:EGFP) 
larvae showing enlarged tubular lumen (white lines) in gent-AKI fish. PT cells are labeled with EGFP fluorescence 
(green). (C-D) Transverse sections stained with hematoxylin and eosin, showing flattening of epithelial cells and 
thinning of the brush border in gent-AKI larvae (arrowheads). Insets show higher magnification of the tubules. Scale 
bars, 10 μM. (E-F) TUNEL staining for apoptotic cells is increased in gent-AKI larvae. Insets show a higher 
magnification of the tubule outlined in white. Scale bars, 5μM. (G-H) Immunofluorescence for Na/K ATPase on 
transverse sections of the PT demonstrates loss of basolateral expression and cell sloughing after gentamicin-induced 
injury. Insets show higher magnification of the region marked with asterisk. Scale bars, 10 μm. Experiments 
performed by C. Cosentino and L. Brilli Skvarca215. 
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We also evaluated whether zebrafish larvae expressed kidney injury molecule 1 (Kim1), 
a transmembrane glycoprotein that is expressed in injured PT cells in mammals216. Kim1 is 
currently being evaluated as a biomarker of tubular injury in humans217-219. Since Kim1 has not 
previously been used as a marker of renal tubular injury in zebrafish, we first evaluated 
expression and localization of Kim1 in larval zebrafish after gentamicin-induced AKI. kim1 
mRNA expression increased in trunk tissue of zebrafish larvae in a dose-responsive manner 
within 24 hours of gentamicin injection and remained elevated at 2 dpi (Figure 8A-B). Since 
gentamicin induces selective injury to PT cells215, 220, we used the transgenic reporter line 
Tg(PT:EGFP) to show that Kim1 protein is expressed in EGFP-positive PT cells in zebrafish 
larvae at 1 and 2 days after injury (Figure 8C). These data provide further comparison between 
tubular injury induced by gentamicin in zebrafish larvae and mammalian AKI. 
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 Figure 8: Renal tubular cells express Kim1 after gentamicin injury in zebrafish larvae. 
(A-B) An injury dose curve was performed by injecting wildtype larvae with a single dose of 2, 4, 6, or 8ng 
gentamicin at 3 dpf. We then performed qRT-PCR to examine effects on kim1 mRNA expression in dissected trunk 
tissue at 1 and 2 dpi. Graph is one representative experiment, shown as mean ±SD for 3 technical replicates (n=4-7 
experiments, 15 larvae/group). Expression normalized to β-actin and sdha. Experiments performed with technical 
assistance from J. Fall. (C) Tg(PT:EGFP) fish were injected with 8ng gentamicin at 3 dpf followed by 
immunofluorescence staining on transverse cryosections for Kim1 (red) and GFP (green) at 6 hours post injection 
(hpi), 1 dpi, and 2 dpi. Tubules are outlined in white. Scale bars, 20 μm221. 
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2.2.3 Renal tubular regeneration after gentamicin-AKI 
Kidney regeneration in mammals is characterized by dedifferentiation and proliferation of 
surviving RTECs that reactivate genes normally required during organogenesis54. To confirm 
these findings in our model, we investigated whether PT cells expressed Pax2a post-AKI, a 
transcription factor reactivated after injury in mammalian AKI models53, 54, 222, 223. We detected 
increased numbers of Pax2a-positive PT cells in the kidneys of gentamicin-injected larvae at 2 
dpi (Figure 9). This observation is consistent with a dedifferentiation response occurring in the 
injured tubules of gent-AKI larvae50, 53, 54, 222, 223. 
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Figure 9: Renal tubular cells express Pax2a after gentamicin injury in zebrafish larvae. 
(A) Transverse cryosections of uninjured or gent-AKI Tg(PT:EGFP) fish immunostained with anti-GFP (green) and 
anti-Pax2a (red, white arrows), and counterstained with DAPI (blue). Tubules are outlined in white. (B) Pax2a-
positive cells were quantified in the PT by examining serial sections (n=10 tubules/group). Data expressed as mean 
±SEM. 2-tailed T Test, *P<0.05.  
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We evaluated the tubular proliferation response in this AKI model by quantifying the 
number of PT cells in the S-phase of the cell cycle after gentamicin injection. To do this, we 
treated zebrafish larvae with the thymidine analogue 5-ethynyl-29-deoxyuridine (EdU) followed 
by immunofluorescence microscopy. At 3 dpi, EdU was colocalized with 3G8 staining, which 
marks the apical brush border of PT cells224 (Figure 10A). Baseline proliferation index, defined 
as the number of EdU-positive cells divided by the number of DAPI-positive PT cells at 5 dpf, 
for control larvae was 3.5%, which increased after gentamicin-induced AKI to 7.3% (Figure 
10B). These data suggest that PT cells in the pronephric kidney of zebrafish larvae undergo 
dedifferentiation and proliferation after gentamicin-induced injury, analogous to the regenerative 
epithelial response in mammalian AKI models. 
 
Figure 10: Proliferation of PT cells after gentamicin-AKI. 
(A) Uninjured and gent-AKI larvae were incubated with the thymidine analogue EdU (green) at 3 dpi, and 
transverse sections were counterstained with 3G8 antibody (red) to mark the PT apical brush border. White lines 
outline the tubules. Scale bars, 20 μm. (B) Quantitative analysis of proliferating PT cells shows a significant 
increase in the percentage of 3G8, EdU-positive cells between uninjured (3.5%±0.46) and gent-AKI fish 
(7.3%±0.71). “n” indicates the number of tubules analyzed per group. Data are expressed as mean ±SEM; 2-talied T 
test: ***P<0.0005215. 
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2.2.4 Immune response during gentamicin-AKI 
In mammals, AKI results in the rapid influx of leukocytes, including neutrophils and 
macrophages72, 76-79. Since the innate immune response is functional in zebrafish by 3 dpf209, we 
determined whether neutrophils and macrophages also infiltrate the pronephric kidney after 
gentamicin-AKI.  
 To evaluate the neutrophil response in this model, we first performed live time-lapse 
confocal imaging in Tg(cdh17:mCherry); Tg(lyz:EGFP) double transgenic fish after gentamicin 
injection. These fish mark kidney tubular epithelial cells in red (mCherry)212 and neutrophils in 
green (EGFP)225, 226 (Figure 11A). We captured z-stack images of the PT region over 17 hours 
beginning at 24 hpi. lyz:EGFP-positive neutrophils moved rapidly in uninjured fish, with few 
cells accumulating near the PT (Figure 11B). In contrast, neutrophils in gent-AKI fish moved 
slowly and remained close to the mCherry-positive kidney epithelium (Figure 11B). These 
results suggest that neutrophils migrate to the PT during gentamicin-AKI in zebrafish larvae.  
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Figure 11: Neutrophils infiltrate the kidney after gentamicin-AKI in zebrafish larvae. 
(A) Images of Tg(cdh17:mCherry); Tg(lyz:EGFP) double transgenic fish at 4 dpf or 2 dpi, depicting the global 
neutrophil population (green) and the pronephric tubules (red). White box indicates the PT region shown in the 
images below. (B) Single frame 3D projections of the PT region of Tg(cdh17:mCherry); Tg(lyz:EGFP) double 
transgenic fish captured at the indicated time point by time-lapse confocal microscopy. White arrows indicate 
examples of lyz:EGFP-positive neutrophils located near the kidney epithelium. Magnification 20X. 
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In order to quantify this response in Tg(lyz:EGFP) fish, we fixed samples at time points 
after gentamicin injection. We performed immunofluorescence microscopy and counted the 
number of lyz:EGFP-positive neutrophils adjacent to the PT epithelium by examining serial 
sections (Figure 12A). At 4 dpf (1 dpi), there was no change in the number of renal neutrophils 
after gentamicin injection. However, gent-AKI larvae showed significantly more renal 
neutrophils at both 5 dpf (2 dpi) and 6 dpf (3 dpi) compared to uninjured controls (Figure 12B). 
These data suggest that neutrophils infiltrate the pronephric kidney of zebrafish larvae after 
gentamicin-AKI between 1 and 2 dpi.  
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 Figure 12: Gentamicin injury results in increased renal neutrophils. 
(A) Uninjured and gent-AKI Tg(lyz:EGFP) larvae were fixed at 1, 2, and 3 dpi, and transverse sections were 
counterstained with anti-3G8 (red) to mark the PT apical brush border and anti-GFP (green) to mark neutrophils 
(examples, white arrows). White lines outline the tubules. Scale bars, 20 μm. (B) Quantitative analysis shows a 
significant increase in the number of renal neutrophils at 2 and 3 dpi. Data are expressed as mean ±SEM; 2-tailed T 
test: *P<0.05, **P<0.005, ***P<0.0005. “n” represents the number of tubules analyzed per group. 
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The glomerular hematopoietic niche may provide a nearby source for these infiltrating 
neutrophils during injury. Beginning at 4 dpf during larval development, the glomerulus is 
seeded with hematopoietic cells that migrate from the caudal venous plexus in the tail227. 
Consistent with these observations, we detected neutrophil clusters medial to the PT on 2-3 
sections beginning at 5 dpf (Figure 13A). These medial clusters were less prominent or absent in 
many gent-AKI fish at 2 and 3 dpi, with neutrophils distributed on the lateral sides of the PT 
(Figure 13B). Whether AKI triggers decreased neutrophil migration from the tail, inhibits 
proliferation in the glomerulus, or stimulates migration from the niche to the PT requires further 
study. 
 
Figure 13: Dispersion of the neutrophil niche in the pronephric kidney after AKI.  
Uninjured (A) or gent-AKI (B) Tg(lyz:EGFP) fish stained with anti-3G8 and anti-GFP antibodies. Arrows 
indicate neutrophils in the hematopoietic niche near the glomerulus. White lines outline the tubules. Scale 
bars, 20 μm.  
 
We performed similar histological studies using the macrophage reporter line 
Tg(mpeg1:dendra2)228 crossed with Tg(PT:EGFP) to quantify the macrophage response during 
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larval zebrafish gentamicin-AKI (Figure 14A). Compared to uninjured fish, gent-AKI larvae 
showed increased numbers of renal macrophages at 3 dpi (Figure 14B). Globally, macrophages 
in gent-AKI fish were also larger in size at both 2 and 3 dpi (2 dpi: 187 pixel2 in uninjured vs. 
259 pixel2 in gent-AKI, 2-tailed T test P<0.0001; 3 dpi: 184 pixel2 in uninjured vs. 252 pixel2 in 
gent-AKI, 2-tailed T test P<0.0001; at least 325 cells per group). This observation is consistent 
with increased cell size due to phagocytosis also described in mouse IR-AKI229. Taken together, 
these data indicate that a robust innate immune response occurs after gentamicin-induced AKI in 
zebrafish larvae. 
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 Figure 14: Gentamicin injury results in increased renal macrophages. 
(A) Double transgenic Tg(PT:EGFP); Tg(mpeg1:dendra2) larvae were fixed at 2 and 3 dpi, and transverse sections 
were counterstained with anti-GFP (green) to mark the PT and anti-Dendra2 (red) to mark macrophages (examples, 
white arrows). White lines outline the tubules. Scale bars, 20 μm. (B) Quantitative analysis shows a significant 
increase in the number of renal macrophages at 3 dpi. Data are expressed as mean ±SEM; 2-tailed T test: 
**P<0.005, ***P<0.0005. “n” represents the number of tubules analyzed per group. 
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2.3 METHODS 
2.3.1 Zebrafish husbandry 
All studies were approved by the University of Pittsburgh Institutional Animal Care and Use 
Committee. Zebrafish adults and embryos were maintained under standard conditions as 
described230. Embryos were used from Pitt AB wildtype as well as the following published 
transgenic lines: Tg(lyz:EGFP)225 and Tg(mpeg1:dendra2)228. The Tg(PT:EGFP) transgenic line 
was isolated serendipitously during the generation of Tg(sox10:EGFP) fish for an unrelated 
project. The sox10 promoter (a gift from Robert Kelsh) was placed upstream of the EGFP 
sequence using Gateway Toolkit plasmids and the pDestTol2pA2 vector and injected into 1-cell 
stage embryos together with Tol2 transposase mRNA. Founder fish were identified by incrossing 
and stable Tg(PT:EGFP) embryos were raised. Tg(cdh17:mCherry) was generated in 
conjunction with and displays pronephric mCherry expression analogous to the published line 
Tg(cdh17:EGFP)212. For in vivo imaging, embryos were kept in E3 medium containing 0.003% 
1-pheny1-2-thiourea (PTU) after 24 hours post fertilization. 
2.3.2 Gentamicin microinjection 
Zebrafish larvae were injected with a single dose of gentamicin at 2.5 or 3 dpf, as previously 
described206. Briefly, larvae were anesthetized in tricaine/E3 medium (5 mM NaCl, 0.33 mM 
CaCl2, 0.33 mM MgSO4, and 0.17 mM KCl) and injected with 1nl gentamicin (Sigma-Aldrich) 
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diluted in saline, delivered into the common cardinal vein. 10 kDa lucifer yellow or rhodamine 
dextran (Invitrogen) was included in the gentamicin injection solution at 1 mg/ml to verify 
successful microinjection. After injection, larvae were incubated in 50 μg/ml 
penicillin/streptomycin diluted in E3 medium. 
2.3.3 Histological analysis 
Immunofluorescence microscopy was performed on cryosections as described previously2. 
Briefly, larvae were fixed in 4% paraformaldehyde and treated with a 10-30% sucrose/PBS 
gradient before embedding in tissue freezing medium (Ted Pella). Transverse sections were 
generated at a thickness of 12-14 μm. Slides were blocked with 10% goat serum in PBST, 
followed by primary antibody and secondary antibody incubations. The following primary 
antibodies were used: anti-3G8, anti-Pax2a, anti-GFP, anti-Kim1, anti-Dendra2. The following 
secondary antibodies were used: goat anti-mouse Cy3, goat anti-rabbit or goat anti-mouse alexa 
fluor 488, goat anti-rat alexa fluor 594, donkey anti-rabbit alexa fluor 568, and goat anti-chicken 
alexa fluor 555. Incubation with 4’, 6-diamidino-2-phenylindole (DAPI, Vector Laboratories) 
was used to counterstain nuclei. Whole mount immunofluorescence was performed with anti-
α6F antibody to detect Na/K ATPase, followed by JB4 embedding and microtome sectioning, as 
previously described206. For detection of apoptotic cells, TUNEL staining was performed on 
cryosections using the In Situ Cell Death Detection Kit (Roche), according to the manufacturer's 
instructions. Sections were examined by confocal microscopy (Zeiss LSM 700). Conditions for 
histology are summarized in Table 1, Appendix B. 
 To quantify Pax2a-positive cells in Tg(PT:EGFP) fish, we imported serial images 
containing PT:EGFP-positive kidney staining into ImageJ 1.46r software (NIH). The ROI tool 
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was used to outline the pronephric kidney in the green channel, and then the “Analyze Particle” 
function was used to quantify the number of Pax2a-positive cells in the red channel. Background 
removal and threshold values were held constant between groups for each experiment. Particle 
size range was 80 to infinity. Per nephron, 3 images were analyzed skipping one section between 
images. Similar ImageJ analysis was performed in Tg(PT:EGFP); Tg(mpeg1:dendra2) fish to 
quantify macrophage cell size. For these images, there was no background removal, 
mpeg1:dendra2 channel threshold was 53 to 255, and particle size range was 60 to infinity. 
2.3.4 RNA isolation and quantitative RT-PCR 
Samples for RNA isolation were generated by cutting zebrafish larvae at the hindbrain to isolate 
trunk tissue. 10 to 15 larvae were pooled and homogenized per sample.  RNA was isolated using 
the RNeasy Micro kit (Qiagen), and cDNA was generated using the SuperScript First Strand kit 
(Invitrogen). qRT-PCR was performed as described previously204. Exon-spanning primers were 
designed using Beacon Designer version 8.13 to detect kim1 mRNA. Primer sequences are listed 
in Table 2, Appendix B. Expression was normalized to β-actin and sdha mRNAs, as 
described204. qRT-PCR was repeated using cDNA samples from 3-7 different experiments. Raw 
data for each replicate is listed in Table 3 in Appendix B. Data shown in graphs are from one 
representative experiment with 3 technical replicates. 
2.3.5 EdU labeling 
To label proliferating cells in zebrafish, larvae were treated with EdU using the Click-iT Imaging 
Kit (Invitrogen), adapted by S. Eckerle and J. Holzschuh for cryosections231. Larvae were 
 49 
incubated in EdU solution (10 mM EdU and 5% DMSO in E3 medium) for 30 minutes at 4°C 
and allowed to recover in E3 for one hour at 28.5°C before fixation. Staining was performed 
using alexa fluor 488 followed by immunostaining with anti-3G8. To calculate the proliferation 
index, we determined the average number of cells in the PT (as marked by 3G8) of control larvae 
at 5 dpf (311±7 cells, mean±SEM, n=20 nephrons). To determine the numerator, we counted the 
number of EdU-positive cells in one nephron per larvae within the 3G8 region. 
2.3.6 Live zebrafish confocal imaging 
24 hours after gentamicin injection, zebrafish larvae were anesthetized in 160 mg/ml tricaine 
(Sigma-Aldrich), embedded in a thin layer of 0.5% low-melt Sea Plaque agarose (Cambrex), and 
covered with E3 medium plus PTU to prevent pigment development. Image stacks were acquired 
using a Leica TCS SP5 multiphoton microscope (Leica Microsystems, Wetzlar, Germany) with 
an HCX IRAPO L 20X/0.95 water immersion objective, non-descanned detectors and a custom 
built motorized stage (Scientifica, East Sussex, UK).  Sequential stack scanning was performed 
bidirectionally with a resonant scanner (16000 Hz, phase set to 1.69) with 32x line averaging and 
a zoom of 1.7x. EGFP and mCherry were excited with a Mai Tai DeepSee Ti:Sapphire laser 
(Newport/Spectra Physics, Santa Clara, CA) at 900 and 561 nm, respectively.   Using the “Mark 
and Find” function, (x,y) coordinates and z-series parameters (step size 1.48μm) were defined for 
individual embryos.  Images were captured every 27 minutes for 17 hours.  Maximal projections 
were compiled in series to generate time-lapse movies using LAS AF Version: 3.0.0 build 8134 
and Metamorph software. Still images were captured from these movies to generate panels in 
Figure 11. 
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2.4 DISCUSSION 
We have shown that gentamicin induces renal failure in zebrafish larvae, with histological 
features consistent with mammalian AKI. In this model, RTECs express the renal injury marker 
Kim1, lose epithelial character, and subsequently undergo dedifferentiation and proliferation. 
Phagocytes also invade the pronephric kidney in the post-AKI environment. These studies 
highlight the pathophysiologic similarities between gentamicin-AKI in zebrafish larvae and 
mammalian AKI models. Combined with the general strengths of zebrafish, including large 
clutches, rapid development, and live imaging, these features validate larval gentamicin-AKI as 
an excellent model for studying AKI mechanisms and identifying therapeutic targets. 
 Another strength of this model lies in its clinical relevance. In humans, gentamicin is an 
effective antibiotic treatment for gram-negative infections, but it also causes renal impairment in 
up to 25% patients214. Gentamicin directly injures PT cells and induces cell death in a subset of 
these cells. Comparably in our zebrafish AKI model, gentamicin induces dose-dependent renal 
injury in a proportion of larvae and causes apoptosis in a subpopulation of PT cells. In contrast, 
other AKI models completely ablate entire tubular cell populations or nephron segments. These 
models, including directed laser injury in zebrafish232 and diphtheria-toxin-mediated PT damage 
in mice232, cause massive cell death and therefore do not fully recapitulate the clinical AKI injury 
environment. 
Although gentamicin-AKI is clinically relevant, microinjection is time consuming and 
technically challenging. Since gentamicin is cationic, it must be delivered directly into the 
circulatory system of each fish; larvae treated with gentamicin in the embryo media do not 
develop AKI in our hands. It would therefore be advantageous to develop an alternative AKI 
model that also causes partial RTEC loss but does not require manipulation of individual larvae. 
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To achieve this goal, the Hukriede lab is currently developing a transgenic line that utilizes the 
thyroid-stimulating hormone beta subunit (tshβ) promoter and the Gal4-UAS system to drive 
mosaic nitroreductase expression in PT and pituitary cells233. In this model, metronidazole 
treatment would induce apoptosis only in the subset of PT cells that express nitroreductase, 
resulting in patchy apoptosis. This tool will provide a complimentary genetic model to 
gentamicin-AKI that will greatly facilitate future studies.  
Despite serious renal impairment, most patients survive after AKI; however, gentamicin-
AKI in the zebrafish larval model is ultimately lethal. Despite epithelial regeneration, over 50% 
of fish die within 3 days after high-dose gentamicin injection. Severely injured larvae develop 
massive general edema, which likely damages other organs and compromises long-term survival. 
Failure of recovery may be partially explained by the simplicity of the system. Since the 
pronephric kidney consists only of 2 nephrons, there are significantly fewer reserves compared to 
the metanephric kidney. Additionally, unlike rodents, serum creatinine or GFR measurements are 
so far not possible in zebrafish due to small intravascular blood volume. However, two other 
techniques have been described. Fluorescent beads can be injected into the circulatory system, 
and uptake by the PT can be examined by live imaging2. Additionally, Zhou and Hildebrandt 
generated a transgenic line that expresses fluorescent-tagged vitamin D binding protein (VDBP), 
the closest zebrafish protein to mammalian albumin234. This group evaluated glomerular 
filtration using ELISA to detect VDBP in the embryo media, analogous to proteinuria, in an 
inducible transgenic zebrafish model of podocyte injury. These studies provide alternative 
methods for general functional assessments in zebrafish AKI models. Since we show that 
zebrafish larvae express Kim1 in the PT following gentamicin injection, Kim1 levels could be 
compared as a biomarker of renal injury. Since our qRT-PCR assay does not specifically 
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measure renal kim1, more accurate evaluation of renal injury would require either pronephric 
dissection or quantification of Kim1 immunofluorescence in the kidney. Developing other 
functional markers would greatly enhance the power of the zebrafish AKI model. 
Although this work characterizes many aspects of nephrotoxic AKI in zebrafish larvae, 
future studies are needed to evaluate whether this model recapitulates other traits of mammalian 
AKI. First, it is not known whether RTECs in zebrafish undergo maladaptive repair through 
G2/M arrest. Addressing this question would require careful cell cycle analysis post-AKI. So far, 
our attempts to identify and optimize antibodies for phospho-histone-H3, which marks cells in 
G2/M phases, for use in zebrafish have been unsuccessful. If G2/M arrest occurs in zebrafish, a 
following question is whether these cells would have similar negative consequences for renal 
fibrosis in this model. In preliminary studies, we did not find foxD1-positive cells in the 
pronephric kidney, and there are currently no reports of a renal stroma population in the 
zebrafish kidney. Thus, even if G2/M arrest does occur during zebrafish AKI, it may have less 
significant effects on outcome. 
  Further studies are also needed to characterize the immune response more completely. 
Here, we used immunofluorescence in the Tg(mpeg1:denra2) line to examine renal macrophage 
numbers during AKI. Increased macrophages could result from migration or proliferation in situ. 
Live imaging experiments would facilitate cell tracking to determine definitively whether 
macrophages migrate to the kidney, whereas EdU studies would determine if renal macrophages 
proliferate after AKI. In rodent AKI models, current evidence suggests that M1 macrophages 
migrate to the kidney early in the course of injury, whereas expansion of the M2 population 
occurs later by proliferation within the kidney80. More fundamentally, it is not yet known 
whether macrophages in zebrafish larvae polarize into M1/M2 phenotypes. Promisingly, a few 
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groups have identified macrophages in zebrafish that express TNFα (M1 marker) and/or arginase 
1 (M2 marker)209. The Hukriede lab is currently optimizing immunofluorescence staining to 
assess whether mpeg1:dendra2-positive cells coexpress M1 and/or M2 markers during AKI. 
Finally, we have adapted macrophage depletion strategies from mouse for use in the larval 
zebrafish AKI model. This technique involves microinjection of clodronate-containing liposomes 
which induce macrophage apoptosis, and will allow us to evaluate the role of these potential 
macrophage subpopulations after AKI. These studies will provide further insights into the injury 
environment of gentamicin-AKI in zebrafish larvae. 
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3.0  HISTONE DEACETYLASE INHIBITOR M4PTB ENHANCES RECOVERY 
AFTER AKI IN ZEBRAFISH LARVAE 
3.1 HYPOTHESIS 
Since gentamicin injection in zebrafish larvae recapitulates the major hallmarks of mammalian 
AKI, we next evaluated the potential of this model as a drug discovery tool to develop new AKI 
therapies. Previously in the Hukriede lab, a chemical library screen identified the PTBA class of 
novel HDACi based on its ability to increase RPC proliferation during renal development in 
zebrafish embryos204. The analogue methyl-4-(phenylthio)butanoate (m4PTB) is a prodrug in the 
PTBA class that shows greater activity in vivo due to esterification of the free acid204 (Figure 
15A). Based on the embryonic phenotype, we hypothesized that m4PTB would improve outcome 
post-AKI by increasing the RTEC proliferation response in this larval zebrafish model.  
3.2 RESULTS 
3.2.1 Establishing dosing with m4PTB in zebrafish larvae 
To establish an effective working concentration of m4PTB in zebrafish larvae, we first 
determined the maximum tolerated dose (MTD), defined as the maximum concentration at which 
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there were no signs of significant toxicity or death235. Cohorts of 15-20 larvae were incubated 
with 1% DMSO (vehicle control treatment) in E3 medium with or without m4PTB at increasing 
concentrations for 24 hours from 4 to 5 dpf. Using this approach, the MTD for m4PTB in 
zebrafish larvae was established at 8 μM, which represents the highest effective dose well 
tolerated by zebrafish larvae (Figure 15B).  
To further rationalize the working dose of m4PTB, we performed western blot analysis to 
evaluate in vivo histone H4 acetylation, a marker of HDACi activity. We treated 4 dpf larvae 
with increasing concentrations of m4PTB and generated protein extracts from whole fish at 
different time points after treatment. There was a marked upregulation of H4 acetylation after 6 
hours, detectable at the lowest concentration of m4PTB used (2 μM); however, only the 8 μM 
MTD dose showed H4 acetylation at 12 hours, and none of the concentrations induced H4 
hyperacetylation after 24 hours of treatment (Figure 15C). These data indicate that m4PTB 
induces short-term changes in histone acetylation status for 6 to 12 hours. Further supporting our 
choice for working concentration, 4 μM m4PTB treatment resulted in a general increase in 
hyperacetylation, including in the pronephric kidney (Figure 15D-G). Since both 4 μM and 8 μM 
induced comparable H4 acetylation after 6 hours, we chose 4 μM m4PTB as our working 
concentration in AKI survival studies.  
Over the course of the experiments presented here, the Hukriede lab used m4PTB 
synthesized either by Lee McDermott (University of Pittsburgh, Drug Discovery Institute) or by 
Enamine (www.enamine.net). Similar compound analysis was performed on each new batch to 
inform the batch-specific working dose for subsequent experiments. This dose ranged from 0.5 
to 4 μM. 
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 Figure 15: MTD and m4PTB-induced hyperacetylation in zebrafish larvae. 
(A) Structure of m4PTB. (B) MTD assay. Larvae were treated with m4PTB at 4 dpf and scored for health 
and survival at 5 dpf. Asterisk indicates dose at which significant death was observed (n=91 fish), Fisher’s 
exact test: *P<0.05. MTD assay performed with technical assistance from C. Woods. (C-G) Acetylation of 
histone H4. (C) Western blot examining the acetylation state of histone H4 (top panel) isolated from larvae 
treated at 4 dpf with 1% DMSO, 2 μM, 4 μM or 8 μM m4PTB for 6, 12, or 24 hours. Western blot for α-
tubulin as a loading control (bottom panel). (D-E) Whole mount immunostaining for acetylated histone H4 
at 4 dpf after 6-hour treatment with 1% DMSO or 4μM m4PTB demonstrates global hyperacetylation. (F-
G) Confocal images of boxed regions in D and E show hyperacetylation in the pronephric kidney 
(arrowheads) after m4PTB treatment. Scale bars, 300 μm215. 
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3.2.2 Post-injury m4PTB treatment increases survival after gentamicin-AKI 
We sought to determine whether m4PTB treatment enhanced renal recovery in the zebrafish 
gentamicin AKI model. Since our goal was to establish a post-injury treatment regimen, we 
wanted to initiate m4PTB treatment after larvae clearly demonstrated renal injury. We previously 
showed robust upregulation of renal Kim1 expression at 2 dpi (Figure 8), so we assessed whether 
larvae showed further evidence of renal injury at this time point. Gent-AKI larvae that displayed 
pericardial edema and darkened yolks at 2 dpi (Figure 16A-B) also showed histological loss of 
renal tubular cell polarity (Figure 16C-D). In combination, these findings indicate that 
gentamicin induces renal damage by 2 dpi, and allowed us to identify injured larvae by 
examining for gross phenotypic changes. Thus, in subsequent experiments we treated larvae with 
m4PTB for 24 hours beginning at 2 dpi.  
 
Figure 16: Edema and PT cell polarity after gentamicin-induced AKI at 2 dpi. 
(A) Uninjured and (B) gentamicin-injected edematous larvae at 4 dpf or 2 dpi (arrow, pericardial edema). (C-D) Loss 
of cell polarity at 2 dpi. Transverse sections of the PT in control larvae showing normal distribution of the Na/K 
ATPase antibody (C), whereas gent-AKI larvae display a clear disruption of cell polarity (D). Insets show higher 
magnification of the PT (asterisk). Scale bars, 20 μm. Experiments performed by C. Cosentino and L. Brilli 
Skvarca215. 
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Having established an effective working dose and post-AKI treatment window for 
m4PTB, we next treated gent-AKI larvae with a single dose of either 1% DMSO or 4 μM 
m4PTB from 2 to 3 dpi and monitored survival rates. Compared to vehicle, gent-AKI larvae 
treated with m4PTB showed significantly increased survival at 5 and 6 dpi, from 58% to 79% 
and from 55% to 74%, respectively (Figure 17). These results show that short-term, delayed 
m4PTB treatment enhances overall recovery after AKI in this model. 
 
Figure 17: m4PTB treatment increases larval survival after AKI. 
Gent-AKI larvae were treated with either 1% DMSO vehicle or 4μM m4PTB at 2 dpi, and survival rate was 
evaluated at 4, 5, and 6 dpi: 4 dpi, 87% (n=69/79 fish) in vehicle-treated larvae versus 93% (n=74/80 fish) in 
m4PTB-treated larvae; 5 dpi, 58% (n=46/79 fish) in vehicle-treated larvae versus 79% (n=63/80 fish) in m4PTB-
treated larvae; 6 dpi, 55% (n=38/69 fish) in vehicle-treated larvae versus 74% (n=52/70 fish) in m4PTB-treated 
larvae. Data pooled from 3 independent survival assay experiments. Fisher’s exact test: *P<0.05, **P<0.005. 
Experiments performed by C. Cosentino and L. Brilli Skvarca215. 
 
3.2.3 m4PTB treatment increases PT cell proliferation post-AKI 
Since m4PTB increases RPC proliferation in zebrafish embryos204, we determined whether 
enhanced post-AKI survival after treatment with m4PTB was associated with increased RTEC 
proliferation. We injected fish with gentamicin at 2.5 dpf, followed by 1% DMSO or m4PTB 
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treatment at 2 dpi. To evaluate cell proliferation, we treated larvae with EdU at 3 dpi and assayed 
for EdU-positive cells in the PT marked by anti-3G8 staining (Figure 10 and Figure 18). In 
uninjured larvae, the percentage of EdU-positive PT cells increased from 3.5% in DMSO-treated 
controls to 7.1% in m4PTB-treated fish. In gent-AKI larvae, the proliferation index was also 
increased from 7.3% in DMSO-treated controls to 10.7% in m4PTB-treated fish (Figure 10 and 
Figure 18). There was no significant change in the number of apoptotic cells at 3 dpi between 
DMSO and m4PTB treatment groups (DMSO: 4.56±1.4 cells; m4PTB: 4.06±1.0 cells; TUNEL 
labeling in 3G8-positive PT cells, mean ±SEM). Therefore, the increased proliferative response 
after treatment with m4PTB suggests that enhanced recovery in this zebrafish AKI model results 
from increased PT cell regeneration and repair of injured tubules. 
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 Figure 18: m4PTB treatment increases PT cell proliferation. 
(A) Uninjured and gent-AKI fish were treated with 1% DMSO (Figure 10) or 4μM m4PTB at 4 dpf (2 dpi). At 5 dpf 
(3 dpi), larvae were incubated with EdU (green), and transverse sections were counterstained with 3G8 antibody (red) 
to mark the apical brush border of the PT. White lines outline the tubules. Scale bars, 20 μm. (B) Quantitative 
analysis of proliferating proximal tubule cells. Cell counting analysis shows a significant increase in the percentage 
of 3G8, EdU-positive cells in m4PTB-treated larvae at 5 dpf in uninjured fish (3.5%±0.46 versus 7.1%±0.68) and at 
3 dpi in gent-AKI fish (7.3%±0.71 versus 10.7%±1.7). “n” indicates the number of fish analyzed per group. Data are 
expressed as mean ±SEM; 2-tailed T test: *P<0.05; ***P<0.0005215. 
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3.2.4 m4PTB increases tubular cell dedifferentiation post-AKI 
Several mechanisms could explain m4PTB-induced RTEC proliferation, including accelerated 
cell cycle progression and/or increased dedifferentiation. To examine the latter possibility, we 
injected Tg(PT:EGFP) fish with gentamicin at 3 dpf, followed by DMSO or m4PB treatment at 2 
dpi. We then quantified the number of Pax2a-positive cells in the PT at 3 dpi, since Pax2a is 
reactivated after injury in mammalian AKI models53, 54, 222, 223. Compared to uninjured larvae, 
gent-AKI larvae had a greater number of Pax2a-positive cells (4.1±0.6 cells vs. 9.5±1.3 cells), 
which was almost doubled by 24-hour m4PTB treatment (18.0±2.8 cells) (Figure 19). These 
results point to an increased dedifferentiation response, and suggest that m4PTB’s effects on 
tubular epithelial proliferation are due in part to stimulating dedifferentiation. 
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 Figure 19: m4PTB expands the Pax2a-positive population of PT cells post-AKI. 
(A-C) Transverse cryosections of uninjured or gent-AKI Tg(PT:EGFP) fish treated with 1% DMSO vehicle or 1-2 
μM m4PTB, immunostained with anti-GFP (green) and anti-Pax2a (red, white arrows), and counterstained with 
DAPI (blue). Tubules are outlined in white. Scale bars, 20 μm. (D) Pax2a-positive cells were quantified in the PT by 
examining serial sections. Data expressed as mean ±SEM. 2-tailed T test, *P<0.05, ***P<0.0005. “n” indicates the 
number of tubules analyzed per group. 
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3.2.5 m4PTB treatment does not affect the innate immune response 
HDACi have been shown to improve long-term outcomes in mammalian AKI partly due to their 
anti-inflammatory properties139, 143. Therefore, we assessed whether post-injury treatment with 
m4PTB also affected the innate immune response in this model. We injected Tg(lyz:EGFP) or 
Tg(mpeg1:denra2) fish with gentamicin at 3 dpf, followed by DMSO or m4PTB treatment at 2 
dpi. We then quantified renal neutrophils and macrophages, respectively, by 
immunofluorescence staining at 3 dpi. There was no significant change in the number of 
neutrophils or macrophages between treatment groups (Figure 20). Thus, the mechanism by 
which m4PTB ameliorates AKI in zebrafish larvae does not involve modulating the innate 
immune response.  
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 Figure 20: m4PTB treatment does not affect post-AKI neutrophil or macrophage infiltration. 
(A) Tg(lyz:EGFP) larvae were injected with gentamicin at 3 dpf and treated with either DMSO or m4PTB at 2 dpi. 
Larvae were fixed at 3 dpi and stained with anti-3G8 and anti-GFP antibodies. (B) Quantitative analysis shows no 
significant difference in the number of renal neutrophils after treatment. (C) Double transgenic Tg(PT:EGFP); 
Tg(mpeg1:dendra2) larvae were injected with gentamicin at 3 dpf and treated with either DMSO or m4PTB at 2 dpi. 
Larvae were fixed at 3 dpi and stained with anti-GFP and anti-Dendra2 antibodies. (D) Quantitative analysis shows 
no significant difference in the number of renal macrophages between groups. Data are expressed as mean ±SEM; 2-
tailed T test: not significant. White lines outline the tubules. Scale bars, 20 μm. “n” represents the number of tubules 
analyzed per group. 
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3.3 METHODS 
3.3.1 Zebrafish husbandry 
Zebrafish husbandry was performed as described in Chapter 2.  
3.3.2 Gentamicin microinjection 
Gentamicin microinjection was performed as described in Chapter 2. 
3.3.3 MTD assay 
Cohorts of 15-20 zebrafish larvae were arrayed in individual wells of a 12 well plate and 
incubated with treatment solution containing 1% DMSO diluted in E3 medium, ±m4PTB at 
increasing concentrations. m4PTB was synthesized as previously described204. Treatment was 
initiated at 4 dpf and continued for 24 hours at 28.5°C. At 5 dpf, larvae were examined for signs 
of toxicity, including slowed heartbeat, impaired tail circulation, impaired touch response, 
edema, and death. The MTD was determined as the maximum m4PTB concentration that did not 
result in mortality or generalized toxicity in ≥50% fish. Each assay was performed in triplicate 
with mixed clutches for every new synthesis batch of compound. Working doses were 
established between 0.5 and 4μM between batches. 
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3.3.4 Histone hyperacetylation assay 
Cohorts of 20 larvae were treated with increasing concentrations of m4PTB at 4 dpf and 
harvested for western blot after 6, 12, or 24 hours, or for immunofluorescence after 6 hours. For 
western blot analysis, larvae were pooled and transferred to cold PBST +0.1% tricaine for 10 
minutes. This solution was removed, and 1x Laemmli buffer (Biorad) plus 5% 2-
mercaptoethanol was added. SDS-PAGE and western blotting were performed as described 
previously204, with the following modifications. Proteins were separated on 4-20% 
polyacrylamide gradient gels (Biorad). Membranes were incubated at 4°C overnight with 1:1,000 
rabbit anti-acetylated H4 Lysine 5/8/12 and 16 antibodies (pan H4 acetylation, PentaH4, 
Millipore), or 1:1,000 anti–α-tubulin antibody (Sigma-Aldrich) in PBST containing 5% nonfat 
milk.  
Whole mount immunofluorescence examining global histone hyperacetylation was 
performed with PentaH4 antibody (1:250) as previously described for α6F antibody206, with an 
additional incubation with 100μg/ml proteinase K included before the blocking step. Larvae were 
imaged by confocal microscopy (Zeiss LSM 700) by stitching z-stack images consisting of 58, 
4μm optical sections. 
3.3.5 Histological analysis 
Histology was performed as described in Chapter 2. Conditions for histology are summarized in 
Table 1, Appendix B. 
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3.3.6 Survival assay with m4PTB 
For survival studies, m4PTB was used at a treatment concentration one-half the maximum 
tolerated dose (4 μM). Larvae were soaked in treatment solution containing 1% DMSO ±m4PTB 
diluted in E3 medium beginning 48 hours after gentamicin injection (2 dpi). After 24 hours at 3 
dpi, treatment solution was removed and replaced with E3 medium. Larvae were assayed for 
death at 4, 5, and 6 dpi. Survival rates were compared using a 2-talied Fisher’s exact test. 
 
3.3.7 EdU labeling 
EdU labeling and proliferation analysis was performed as described in Chapter 2. 
3.4 DISCUSSION 
This work shows that post-injury treatment with the novel HDACi m4PTB increases recovery 
after gentamicin-AKI in zebrafish larvae. m4PTB enhances recovery in this model by 
stimulating RTEC dedifferentiation and proliferation, without affecting the innate immune 
response. m4PTB treatment also expands the population of lhx1a-positive RPCs by increasing 
proliferation in the embryo204, suggesting that m4PTB acts by a common mechanism during 
renal development and regeneration. Taken together, these studies demonstrate how compound 
screens in zebrafish embryos can be used to identify new drug targets that show promise as novel 
therapeutics in kidney disease models.  
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 To evaluate whether our results in zebrafish translate to mammalian AKI, our 
collaborators in the lab of Mark de Caestecker at Vanderbilt University evaluated the therapeutic 
potential of m4PTB in mouse IR-AKI. In this model, m4PTB treatment accelerated renal 
functional recovery, increased the proportion of proliferating S-phase RTECs, and decreased 
long-term fibrosis215. These studies provide evidence that m4PTB also ameliorates AKI after IR-
AKI in mice by comparable mechanisms to gentamicin-AKI in zebrafish larvae. More generally, 
they show how modeling AKI in zebrafish can identify new therapies that translate well in 
mammals.  
 Despite many similarities between zebrafish and mouse AKI, the effects of HDAC 
inhibition on the immune response may differ depending on the particular AKI model and 
compound. After treating mice with the potent nephrotoxin aristolochic acid, Novitskaya et al. 
observed a reduction in macrophages after m4PTB treatment, which correlated with increased 
functional recovery and decreased fibrosis236. This is consistent with other reports of beneficial, 
anti-inflammatory properties of more broad-spectrum HDACi in kidney disease models97, 237. In 
zebrafish gentamicin-AKI, however, we saw no change in the number of infiltrating neutrophils 
or macrophages after m4PTB treatment. One possible explanation for this difference could be the 
timing of evaluating the leukocyte response. In the Novitskaya study, m4PTB’s effects on 
expression of macrophage markers and macrophage numbers were most robust late in injury, at 
days 14-21 after injury. Early in the course of injury at 4-7 dpi, several macrophage markers 
remained unchanged. These findings indicate that early m4PTB treatment may promote a healthy 
repair environment, mitigating inflammation as a long-term benefit. 
We also noted differences in how m4PTB affected the dedifferentiation and proliferation 
response after AKI in mice versus zebrafish. In mouse, microarray studies identified a greater 
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than 2-fold expression increase of several G2/M transitional regulators after m4PTB treatment, 
including Cyclin B1, Cyclin B2, Cdca3, Polo Like Kinase 1, and Checkpoint Kinase 1. These 
expression changes led the de Caestecker lab to evaluate the proportion of proliferating RTECs 
in the S, G2, or M phases of the cell cycle. m4PTB treatment increased S-phase proliferation 
with a concomitant decrease in the number of cells in G2/M. Further supporting these results, 
Thus in mouse AKI, m4PTB alleviates cell cycle arrest by promoting cell cycle progression. 
Given the role of G2/M arrested cells in advancing renal fibrosis, these results may explain why 
m4PTB-treated mice ultimately developed less fibrotic tissue. In zebrafish, we also observed 
increased S-phase proliferation by EdU incorporation after m4PTB treatment, but we did not 
evaluate other phases of the cell cycle. As discussed in Chapter 2, it is not currently known 
whether RTECs undergo G2/M arrest after AKI in zebrafish. Therefore, to fully assess 
translatability, further studies are warranted to evaluate m4PTB’s effects on cell cycle regulation 
in zebrafish. 
Conversely in zebrafish AKI, we observed a greater number of Pax2a-positive RTECs 
after m4PTB treatment. This indicates that m4PTB stimulates RTEC dedifferentiation, which 
could also explain the increased proliferative response. Immunofluorescence microscopy studies 
demonstrating colocalization of Pax2a and EdU in RTECs would more definitively determine 
whether m4PTB-stimulated RTEC dedifferentiation leads to increased proliferation and tubular 
repair. It has been shown in mouse AKI that proliferating RTECs are both Pax2- and Kim1-
positive222, suggesting that the injured cell population is responsible for the regeneration 
response. Kim1, however, has not been quantified on the cellular level. Theoretically, it would 
be feasible to quantify Kim1 immunofluorescence in order to examine whether m4PTB 
decreases Kim1 levels in dedifferentiated cells, effectively creating a mildly-injured RTEC 
 70 
population that contributes to repair. Further, we could examine whether m4PTB treatment 
promotes RTEC health by performing Na/K ATPase staining and examining for restored 
apical/basal polarity. These studies are ongoing in the Hukriede lab. 
More generally, these results indicate that m4PTB has both pro-dedifferentiation and pro-
proliferation effects on cell populations in zebrafish and mice – observations that contrast with 
the pro-differentiation, anti-proliferation profile of many HDACi in the cancer field. Several 
studies, however, demonstrate that HDACi have different and even paradoxical effects in cancer 
cells compared to non-cancerous cells. For example, HDACi that are highly toxic to cancer cells 
appear to have cytoprotective effects in non-cancerous cells102.  In fact, non-cancerous cells are 
more resistant to high HDACi doses than cancer cells, and low doses have actually been shown 
to be both reno-238, 239 and neuroprotective240, 241. Specifically, one possible mechanism for 
differential sensitivity to SAHA treatment has been related to the availability of ROS scavenging 
proteins. SAHA treatment increases expression levels of thioredoxin binding protein 2 (TBP2), 
resulting in a subsequent decrease in the availability of ROS scavenging proteins. Combined 
with the fact that SAHA also increases ROS generation in cancer cells, this may lead to 
preferential cancer cell death119. These studies indicate that the effects of HDACi treatment are 
both compound specific and context dependent. 
Here, we have explored how m4PTB ameliorates injury in gentamicin-AKI in zebrafish 
larvae by examining effects on RTEC dedifferentiation/proliferation and leukocyte infiltration. 
Of course, there could be additional mechanisms. For example, HDACi have been shown to act 
as chemical chaperones242 and to protect against oxidative stress243, 244, representing other 
possible therapeutic targets for ameliorating AKI245. The Hukriede lab is currently investigating 
whether PTBA-class HDACi modulate oxidative stress during gentamicin-AKI in zebrafish. 
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Ultimately, comprehensive understanding of the mechanisms underlying how m4PTB mitigates 
renal injury will depend on characterizing HDAC isoform selectivity and downstream molecular 
targets.  
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4.0  INTERSECTION OF M4PTB AND THE RETINOIC ACID PATHWAY IN AKI 
4.1 HYPOTHESIS 
We have shown that m4PTB ameliorates gentamicin-AKI in zebrafish larvae by promoting 
RTEC dedifferentiation and proliferation. To further characterize the underlying molecular 
mechanisms, we sought to identify active signaling pathways that promote renal regeneration 
post-AKI that could be affected by m4PTB treatment. Two lines of evidence led us to investigate 
how m4PTB impinges specifically on the RA pathway. First, HDACs/HDACi modulate RA 
signaling through direct interaction with corepressor complexes. Second, previous work in the 
Hukriede lab demonstrated that PTBA both stimulates RA target gene expression and requires 
intact RA signaling to expand the RPC population in the zebrafish embryo204. Therefore, we 
hypothesized that during AKI in zebrafish larvae, m4PTB also stimulates active RA signaling in 
the kidney.    
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4.2 RESULTS 
4.2.1 RA signaling increases in the pronephros after gentamicin injection 
We first characterized the role of RA signaling in gentamicin-AKI in zebrafish larvae, since this 
has not previously been evaluated. For this we used a zebrafish transgenic reporter, 
Tg(12XRARE:EGFP)160. In this reporter line, activation of consensus RAREs drives EGFP 
expression, allowing RA signaling to be visualized and quantified in vivo by live imaging for 
EGFP159, 160. Uninjured fish expressed basal levels of egfp mRNA in the retina and anterior 
spinal cord (Figure 21A), and a proportion of larvae retained egfp expression in the pronephric 
kidney through 4 dpf (21±8%, n=9 experiments, 12-16 larvae/group). 
 To evaluate the timing and location of RA activation after gentamicin-induced AKI, we 
first performed whole mount in situ hybridization to examine egfp expression in 
Tg(12XRARE:EGFP) larvae after gentamicin injection at 3 dpf. There was an increased 
proportion of fish with strong egfp expression throughout the pronephric kidney 6 hours after 
gentamicin injection (Figure 21A-B). Quantification of trunk egfp mRNA by qRT-PCR also 
demonstrated increased expression at 6 hpi (Figure 21-insets). We also evaluated trunk 
expression of midkine a (mdka), a known RAR target in mammals152. Consistent with the timing 
of increased RA reporter activation, mdka levels were increased at 6 hpi (1.0±0.1 in uninjured 
controls vs. 1.7±0.1 in gent-AKI, 15 larvae/group). 
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 Figure 21: RA signaling is increased in zebrafish larval kidneys after AKI. 
We injected Tg(12XRARE:EGFP) zebrafish larvae with 8ng of gentamicin at 3 dpf to induce renal injury. Whole 
mount in situ hybridization comparing egfp expression in uninjured controls (A) and gent-AKI larvae at 6 hpi. 
Colored arrows show domains of expression: retina (black), anterior spinal cord (red), and kidney (green). Higher 
magnification of the PT in the boxed region inset. Percent egfp quantifies the number of fish with strong, pan-renal 
expression (n=3 experiments at 3dpf, ≥12 larvae/group, mean ±SEM). qRT-PCR for egfp mRNA for dissected trunk 
tissue posterior to the white dotted line are in brackets below the in situ image, mean fold change ±SEM (n=3 
experiments, 15 larvae/group). Normalized to β-actin and sdha221. 
 
Since these results indicate that RA signaling is rapidly activated in the kidney after 
gentamicin injection, we examined the localization and dynamics of RA signaling in the kidney 
in the first 24 hours after injury. Time-lapse confocal imaging in Tg(12XRARE:EGFP); 
Tg(cdh17:mCherry) fish was used to visualize RA signaling in tubular epithelial cells, using loss 
of cdh17:mCherry expression as a marker of tubular cell dedifferentiation after injury160, 212. 
Throughout the 24-hour imaging window, we observed heterogeneous populations of red, 
yellow, and green cells in the kidney. Consistent with our in situ hybridization studies, GFP 
fluorescence intensity decreased over time in the kidney of uninjured controls, and increased in 
gent-AKI fish. Specifically, we observed red cells (differentiated renal epithelial cells) that 
turned yellow (activation of RA signaling, overlay with mCherry) and eventually turned green 
(loss of mCherry expression) (Figure 22). These data indicate that RA signaling is rapidly 
activated in tubular epithelial cells that subsequently lose differentiation characteristics after 
gentamicin injection. 
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 Figure 22: RA signaling increases in renal epithelial cells after AKI. 
Single images from live time-lapse multi-photon imaging showing a region of the PT of uninjured (A) or gent-AKI 
(B) Tg(12XRARE:GFP); Tg(cdh17:mCherry) double transgenic fish. Imaging was performed for 21 hours beginning 
at 4 hours after gentamicin injection. Red indicates cdh17-positive, differentiated renal epithelial cells (example, red 
asterisk), green indicates RA reporter-positive cells (example, green asterisk), and yellow indicates double-positive 
cells (example, yellow asterisk). GFP values indicate average fluorescence intensity ±SEM for the image stack at the 
indicated time point (n=10 uninjured and 6 gent-AKI nephrons)221. 
 
4.2.2 RA signaling is activated in injured tubular epithelial cells 
To determine whether RA activation occurs in injured tubular cells, we evaluated Kim1 
expression in Tg(12XRARE:EGFP) larvae after gentamicin-induced AKI. At 2 dpi, when we 
detected robust activation of Kim1 expression in PT cells (Figure 8), Kim1 colocalized with 
RARE:EGFP in RTECs (Figure 23). These data indicate that RA signaling is activated in a 
population of Kim1-positive injured RTECs in zebrafish larvae after gentamicin-AKI.  
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 Figure 23: RA signaling is activated in Kim1-positive renal epithelium. 
Immunofluorescence staining for Kim1 (red) and GFP (green) in the kidney of uninjured (A) and gent-AKI (B) 
Tg(12XRARE:EGFP) fish at 2 dpi. Examples of colocalization indicated by white arrows. Tubules are outlined in 
white. Scale bars, 20 μm221. 
 
4.2.3 Inhibition of RA signaling impairs survival after AKI 
To examine whether early activation of RA signaling is a critical step in renal regeneration 
processes post-AKI, we treated zebrafish larvae with Ro41-5253, a RAR antagonist that has been 
used to block RAR signaling in zebrafish160, 246, 247. To determine an effective working dose, we 
treated Tg(12XRARE:EGFP) larvae with increasing concentrations of Ro41-5253 for 24 hours 
from 3 to 4 dpf. Treatment with 1 μM Ro41-5253 blocked all domains of egfp expression 
without negative effects on health (Figure 24A). Since we observed rapid activation of RA 
signaling within 24 hours of gentamicin injection, we next treated larvae with Ro41-5253 
immediately after inducing renal injury. Ro41-5253-treated fish showed decreased survival after 
gentamicin injection compared to DMSO-treated fish (Figure 24B), indicating impaired 
recovery206, 215. These data demonstrate that activating the RA pathway early after injury is 
critical for fish to survive after AKI.  
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 Figure 24: Ro41-5353 treatment inhibits RA signaling and impairs survival after AKI. 
(A) Uninjured Tg(12XRARE:EGFP) larvae were treated with 1% DMSO vehicle, 0.1μM or 1μM Ro41-5253 from 3-
4 dpf. Whole mount in situ hybridization was performed at 4 dpf to assess the ability of Ro41-5253 to block egfp 
expression. Colored arrows show domains of expression, including retina (black), anterior spinal cord (red), and 
kidney (green). Percent egfp quantifies the number of larvae that show visible egfp expression in any of these 
domains (n=3 experiments, 15 larvae/group). (B) Uninjured or gent-AKI larvae were treated with vehicle or 1μM 
Ro41-5253 from 3-4 dpf, and survival was assessed daily through 5 dpi (n=4 experiments, ≥20 larvae/group). 2-way 
ANOVA, ***P<0.0005. Bonferroni's correction for multiple comparisons between vehicle and Ro41-5253 treated 
larvae at the same time points: *P<0.05221. 
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4.2.4 Inhibition of RA signaling impairs tubular regeneration after AKI 
To examine the effects of inhibiting RA signaling on renal injury post-AKI, we harvested larvae 
after gentamicin injection and Ro41-5253 treatment and quantified kim1 expression by qRT-
PCR. Compared to DMSO, Ro41-5253 treatment did not significantly alter kim1 mRNA levels at 
1 dpi or 2 dpi (Figure 25A). Thus, decreased survival caused by RAR inhibition may not be 
mediated by increasing Kim1-responsive tubular injury.   
Since the RA pathway is the central regulator of cell proliferation in other organ injury 
models in zebrafish180, 183, and since renal tubular epithelial repair relies on the proliferation 
response of these cells after AKI in both mammals and zebrafish35, 215, we asked whether 
inhibition of RA signaling affected proliferation dynamics in the kidney post-AKI by examining 
cells in S-phase by PCNA immunostaining. Ro41-5253-treated larvae showed a decrease in the 
number of PCNA-positive PT cells at 2 dpi (Figure 25B). These data indicate that RA signaling 
is critical for recovery and promotes PT cell proliferation in larval zebrafish post-AKI. 
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 Figure 25: Blocking the RA pathway impairs tubular proliferation after AKI. 
Zebrafish larvae were injected with 8ng gentamicin at 3 dpf to induce renal injury, followed by treatment with 1% 
DMSO vehicle or 0.5-1μM Ro41-5253 for 24 hours. (A) RNA was isolated from larval trunk tissue at 1 dpi and 2 
dpi, followed by qRT-PCR to examine kim1 mRNA expression. Graph is one representative experiment, shown as 
mean plus SD for 3 technical replicates (n=3 experiments at 1 dpi and n=4 experiments at 2 dpi, 15 larvae/group). 
Expression normalized to β-actin and sdha. (B) Immunofluorescence for PCNA (red) and GFP (green) in the PT of 
Tg(PT:EGFP) fish at 2 dpi. White lines outline the tubules. Scale bars, 20 μm. (C) PCNA-positive cells were 
quantified in the PT by examining serial sections. Data are expressed as mean ±SEM; 2-tailed T test: *P<0.05. “n” 
represents the number of tubules analyzed per group221. 
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4.2.5 Short-term ATRA treatment increases survival during AKI 
Conversely, we examined whether increased RA signaling enhanced AKI recovery by treating 
fish with ATRA after gentamicin injection. We compared two treatment regimens: sustained 
4nM ATRA treatment from 0-5 dpi, and 24-hour 4 nM ATRA from 0-1 dpi. Whereas long-term 
treatment impaired survival, short-term treatment improved survival (Figure 26). Careful 
considerations regarding dose and timing likely influence whether RA agonists will be effective 
AKI therapies. 
 
Figure 26: Effect of ATRA on survival after AKI depends on treatment duration. 
(A) Larvae were injected with 8ng gentamicin at 3 dpf, followed by treatment with 1% DMSO vehicle or 4nM 
ATRA through 5 dpi. Survival was assessed daily through 5 dpi (n=2 experiments, 20-24 larvae per group). (B) 
Compound treatment with 1% DMSO vehicle or 4nM ATRA from 3-4 dpf only (n=2 experiments, 18-22 
larvae/group). 2-way ANOVA, **P<0.005. Bonferroni's correction for multiple comparisons between DMSO and 
ATRA treated larvae at the same time points: *P<0.05. 
 
4.2.6 Mechanism of m4PTB action requires intact RA signaling  
Having determined that increased RA signaling early after AKI is critical for larval survival, we 
next assessed whether m4PTB treatment stimulated RA signaling. To do this, we treated groups 
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of Tg(12XRARE:EGFP) fish with DMSO, ATRA alone, m4PTB alone, or ATRA plus m4PTB at 
4 dpf for 6-10 hours. We evaluated the effect of compound treatment on RA signaling by 
performing whole mount in situ hybridization and examining egfp mRNA expression (Figure 
27A). To quantify these data, we counted the number of larvae that displayed strong egfp 
staining in the kidney/trunk region (Figure 27B). Compared to DMSO-treated controls, low-dose 
ATRA treatment moderately increased egfp expression. High-dose ATRA treatment further 
increased egfp staining intensity in all domains, most easily visualized in the kidney and trunk. 
However, m4PTB treatment alone had no effect on egfp expression compared to DMSO 
treatment. Further, co-treatment with m4PTB and low-dose ATRA did not increase expression 
over levels induced by ATRA alone. These data suggest that in uninjured larvae, m4PTB does 
not directly stimulate RARE-driven egfp expression, and does not synergize with ATRA in this 
reporter line. 
 
Figure 27: m4PTB does not synergize with ATRA to drive RARE:EGFP expression. 
(A) Uninjured Tg(12XRARE:EGFP) larvae were treated with 1% DMSO vehicle, ATRA (low dose at 1-2nM, high 
dose at 4-10nM), m4PTB (1-4μM), or ATRA plus m4PTB. Treatment continued for 6-10 hours before fixation and 
subsequent whole mount in situ hybridization to examine egfp mRNA levels. (B) Percent egfp quantifies the number 
of larvae that show strong kidney/trunk egfp expression (n=3 experiments, 15 larvae/group). Data are expressed as 
mean ±SEM; 2-tailed T test: *P<0.05, *P<0.005. 
 
 Based on these results, we determined whether m4PTB’s effects on RTEC proliferation 
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required an intact RA pathway. To do this, we utilized an inducible transgenic zebrafish line 
Tg(hsp70l:RARA,cryaa:EGFP), here termed Tg(hsp70:dnRARα), in which heat shock stimulates 
expression of a dominant-negative form of the human RA receptor alpha (DN-RARα)248. Since 
this line was used previously to study phenotypes during early development, we established a 
heat shock regimen in zebrafish larvae that would block RA signaling during the window of 
m4PTB activity. To evaluate the timing of DN-RARα protein activation, we heat shocked 4 dpf 
Tg(hsp70:dnRARα) larvae at 37oC for one hour and generated protein extracts after 0, 6, 12, or 
24 hours. Single heat shock resulted in detectable DN-RARα protein from 0 to 6 hours (Figure 
28). Importantly, compound treatment alone did not induce DN-RARα expression in this line 
(Figure 29). Since the effects of 4μM m4PTB treatment on histone acetylation are also abrogated 
between 6-12 hours (Figure 15), one-hour heat shock should reduce RA signaling during the 
same time period as m4PTB is active.  
 
 
Figure 28: Time course of DN-RARα activation after heat shock. 
Fluorescent western blot examining the stability of DN-RARα protein. Groups of Tg(hsp70:dnRARα) fish were heat 
shocked at 4 dpf for one hour at 37oC (+HS) and compared to non heat-shocked controls (-HS). Protein extracts were 
generated after 0, 6, 12, or 24 hours. DN-RARα protein could be detected through 6 hours after heat shock (red, top 
panel). α-tubulin demonstrates equal loading (green, bottom panel). 
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 Figure 29: m4PTB treatment does not activate DN-RARα expression. 
Fluorescent western blot examining the effect of compound treatment on DN-RARα induction in Tg(hsp70:dnRARα) 
fish. Groups of transgenic larvae at 4 dpf were treated with 1% DMSO vehicle, m4PTB, or heat shocked for one hour 
at 37oC (+HS). Protein extracts were generated after 6 hours. DN-RARα protein was detected only after heat shock 
(red, top panel). α-tubulin demonstrates equal loading (green, bottom panel). 
 
We previously showed that m4PTB treatment increased RTEC proliferation both in 
uninjured larvae and after gentamicin injection (Figure 18). Therefore, we evaluated whether 
reducing RA signaling in this heat-inducible transgenic model would block m4PTB-stimulated 
RTEC proliferation. In uninjured Tg(hsp70:dnRARα) larvae, we performed one-hour heat 
treatment at 4 dpf followed by 24-hour DMSO or m4PTB treatment. We quantified EdU S-phase 
proliferation at 5 dpf and compared proliferation to wildtype larvae treated with DMSO or 
m4PTB (Figure 30A). Proliferation rates were comparable between heat-shocked and non heat-
shocked larvae treated with DMSO; however, larvae heat shocked before m4PTB treatment 
showed impaired RTEC proliferation compared to non heat-shocked controls (Figure 30B). 
Therefore in uninjured larvae, m4PTB requires RA signaling to stimulate RTEC proliferation. 
Similarly, we evaluated proliferation in this transgenic model after AKI. At 2.5 dpf, 
Tg(hsp70:dnRARα) larvae were injected with gentamicin. At 2 dpi, larvae were heat shocked for 
one hour and treated with compound for 24 hours, followed by PCNA S-phase proliferation 
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analysis (Figure 30C). Post-AKI, m4PTB treatment significantly increased RTEC proliferation in 
non heat-shocked controls. When heat shock preceded compound treatment, m4PTB did not 
significantly increase RTEC proliferation (Figure 30D). Taken together, these data indicate that 
m4PTB does not directly stimulate the RA pathway, but rather its mechanism of action requires 
upstream RA signaling. 
  
 
Figure 30: DN-RARα induction impairs m4PTB-mediated RTEC proliferation. 
(A) Experimental timeline. Uninjured Tg(hsp70:dnRARα) larvae at 4 dpf were heat shocked for one hour at 37oC, 
followed by 24-hour treatment with 1% DMSO vehicle or 4μM m4PTB. 4 dpf wildtype larvae were not heat shocked 
and treated with DMSO m4PTB. Fish were treated with EdU and proliferation analysis was performed at 5 dpf. (B) 
EdU-positive cells were quantified by examining serial sections stained with anti-3G8. (C) Experimental timeline. 
Tg(hsp70:dnRARα) larvae were injected with 8ng gentamicin at 2.5 dpf. At 2 dpi (4 dpf), larvae were heat shocked 
for one hour at 37oC. Following heat shock, larvae were treated with DMSO or m4PTB. After 24 hours at 3 dpi (5 
dpf), larvae were fixed and PCNA proliferation analysis was performed. (D) PCNA-positive cells were quantified by 
examining serial sections stained with anti-3G8. Data are expressed as mean ±SEM; 2-tailed T test: *P<0.05, 
**P<0.005, ***P<0.0005, ns not significant. “n” represents the number of tubules analyzed per group. 
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4.3 METHODS 
4.3.1 Zebrafish husbandry 
Zebrafish husbandry was performed as described in Chapter 2. In addition, embryos were used 
from the following published transgenic lines: Tg(12XRARE-ef1a:EGFP)sk72 160 and 
Tg(hsp70:dnRARα-αcry:EGFP)248. Positive Tg(hsp70:dnRARα-αcry:EGFP) larvae were 
identified at 2 dpf by examining for EGFP in the eye. For in vivo imaging and in situ 
hybridization, embryos were kept in E3 medium containing PTU after 24 hpf. 
4.3.2 Gentamicin microinjection, chemical treatments, and heat shock 
Gentamicin microinjection was performed as described in Chapter 2. For RA inhibition studies, 
zebrafish larvae were treated with 1uM Ro41-5253 (Enzo Life Sciences) in 1% DMSO diluted in 
E3 for 24 hours from 3 to 4 dpf, and then compound was washed out with several changes of E3. 
For survival assays, individual larvae were placed in wells of a 48 well plate after gentamicin 
microinjection and covered with E3 medium ±Ro41-5253. Larvae viability was scored once per 
day on days 1-5 post injection. For heat shock treatments, groups of 4 dpf fish were arrayed in a 
6 well plate and incubated with preheated E3 medium on a hot plate at 37oC. After one hour, the 
media was removed and the fish were returned to incubation at 28.5oC. 
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4.3.3 In situ hybridization 
Zebrafish larvae were fixed in 4% paraformaldehyde for 24 hours and processed for whole 
mount in situ hybridization as previously described, using antisense RNA probe for egfp204. After 
staining, larvae were examined and scored based on intensity of colorimetric staining. Images are 
shown from one representative experiment.  
4.3.4 DN-RARα protein analysis 
Cohorts of Tg(hsp70:dnRARα-αcry:EGFP) larvae were heat shocked at 4 dpf for one hour at 
37oC and harvested for western blot. 25-30 larvae were pooled and transferred to cold PBST 
containing 0.1% tricaine for 10 minutes. This solution was removed, and 1x Laemmli buffer 
(Biorad) plus 5% 2-mercaptoethanol was added. SDS-PAGE and western blotting were 
performed as described previously204, with the following modifications for fluorescence imaging. 
Proteins were separated on a 10% polyacrylamide gel and transferred to PVDF Immobilon-FL 
membrane (Millipore) at 4°C for 30 minutes at 50V followed by 60 minutes at 100V. 
Membranes were incubated at 4°C overnight with 1:1,000 anti-α-tubulin (mouse, Sigma-Aldrich) 
and 1:750 anti-RARα (rabbit, LifeSpan Biosciences) antibodies in Odyssey blocking buffer 
(LiCor) containing 0.2% Tween. The following day, membranes were incubated with goat anti-
mouse 800CW and goat anti-rabbit 680RD secondary antibodies (LiCor) diluted at 1:15,000 in 
Odyssey blocking buffer for one hour at room temperature. Membranes were dried and kept in 
the dark until imaging using LiCor Odyssey CLx and Image Studio version 4.0 software. 
Original unmodified images are reported in Figure 32, Appendix A. 
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4.3.5 Histological analysis 
Immunofluorescence was performed on cryosections as described in Chapter 2. To quantify 
PTEC proliferation, we counted the number of PCNA-positive cells in the PT, marked by 
PT:EGFP. Conditions for histology are summarized in Table 1, Appendix B. 
4.3.6 RNA isolation and quantitative RT-PCR 
Quantitative RT-PCR was performed as described in Chapter 2. Data shown in graphs are from 
one representative experiment with 3 technical replicates. Raw data for each replicate shown in 
Table 3, Appendix B. Primer sequences are listed in Table 2, Appendix B. 
4.3.7 Live confocal zebrafish imaging 
Time-lapse confocal imaging was performed as described in Chapter 2, with the following 
modifications. Image stacks were acquired using HCX IRAPO L 25X/0.95 water 
immersion objective, and were captured every 90 minutes for 21 hours.  
4.3.8 Analysis of GFP fluorescence intensity  
GFP fluorescence intensity activated by RA signaling in Tg(12XRARE:EGFP); 
Tg(cdh17:mCherry) larvae during live imaging experiments was quantified using the Intensity 
function in LAS AF Version 3.0.0 build 8134. First, a region of interest in the PT was created 
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using mCherry expression as a guide (3350±160μM2, mean±SEM). The average GFP intensity 
was then calculated in this region across an entire image stack in each nephron per larvae. 
4.4 DISCUSSION 
We have shown that after gentamicin injection in zebrafish larvae, RA signaling increases 
rapidly in populations of Kim1-positive injured RTECs that have down-regulated the renal 
differentiation marker Cadherin17. This response is essential for recovery, as chemical inhibition 
of RAR signaling immediately following gentamicin injection significantly decreases RTEC 
proliferation and larval survival. The role of RA signaling during renal development in zebrafish 
has been well characterized171, 172, but this work provides insights into the critical role of RA 
signaling during zebrafish AKI. 
 Additional studies are required to define this role more clearly. First, our proliferation 
analysis after gentamicin injection and Ro51-5253 treatment implicates RA signaling during 
tubular regeneration. Further, we showed that RARE:EGFP-positive cells are injured and lose 
cadherin17:mCherry expression, suggesting that RA signaling may occur in dedifferentiated 
RTECs. However in live imaging experiments, it is important to take into account that 
photostability and cellular context affect fluorophore dynamics249. Although EGFP and mCherry 
have shown good photostability250, we plan to examine if Pax2a colocalizes with RARE:EGFP-
positive RTECs, and if RAR inhibition decreases Pax2a levels. This would more definitively 
show that RA impinges on proliferation by modulating dedifferentiation.  
 In addition to proliferation and/or dedifferentiation, RA could have other positive effects 
during renal regeneration. In a zebrafish model of fin amputation, Blum and Begemann showed 
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that RA signaling not only modulates blastema proliferation, but it also increases bcl2 expression 
effectively protecting against cell death180. Specifically in the context of AKI, pre-treatment with 
ATRA before AKI induced by potassium dichromate in rats prevents oxidative damage and 
tubular cell death251. Pax2 reactivation during injury also decreases RTEC apoptosis14, so RA 
could ultimately be playing a cytoprotective role by multiple mechanisms.   
Although we demonstrated increased RA signaling in RTECs after gentamicin injection, 
these studies did not determine whether this was an autocrine or paracrine effect. In zebrafish 
gent-AKI, preliminary data suggests that Raldh2 levels increase in both RTECs and in 
surrounding peritubular cells, without changes in RAR expression. The implications of these 
findings are two-fold. First, both renal and non-renal cells may represent cellular sources of RA. 
Second, availability of ligand rather than signaling machinery may drive pathway activation, 
which is consistent with other reports153. In line with these ideas, our collaborators in the de 
Caestecker lab observed increased RARE-hsp68-lacZ activity in both RTECs and macrophages 
in the kidney after IR-AKI in mice. This activity peaked 12-24 hours after injury, suggesting that 
rapid induction of RA signaling is conserved between zebrafish and mouse AKI. Further, they 
determined that paracrine RA signaling in RTECs from Raldh-positive macrophages was critical 
for mitigating injury, possibly through M2 alternative activation221. In the future, we will 
evaluate whether Raldh2-positive leukocyte populations also mediate renal regeneration in 
zebrafish.  
 Taken together, data from zebrafish and mouse indicate therapeutic applicability for RA 
agonists during AKI. Low-dose ATRA in mice decreases injury, prevents fibrosis, and improves 
functional recovery during AKI221, findings that corroborate our zebrafish studies that showed 
increased survival during AKI after short-term ATRA treatment. As is the case during 
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development, it appears that tight regulation of RA signaling is required during kidney disease: 
detrimental versus beneficial effects of RA agonists have been shown to vary based on dosage, 
timing, injury model, and compound252. Therefore, treatment parameters must be carefully 
evaluated in order to demonstrate therapeutic potential in the clinical setting.  
Ultimately, understanding the intrinsic role of RA in renal regeneration is motivated by 
attempting to dissect how PTBA-class HDACi mediate recovery during AKI. We have shown 
that m4PTB does not directly stimulate or synergize with ATRA to enhance 
Tg(12XRARE:EGFP) reporter expression. Several factors may explain these results. First, 
evaluating RARE-driven egfp mRNA by qRT-PCR, rather than by in situ hybridization, would 
provide a more quantitative analysis. Second, Tg(12XRARE:EGFP) fish may not 
comprehensively report all RA signaling in larvae. It would be informative to look directly at RA 
target genes, especially since PTBA was found to modulate the RA targets cyp26a1 and cmlc2 in 
zebrafish embryos204. Finally, effects of m4PTB could depend on context. We did not examine if 
m4PTB altered RARE:EGFP expression during injury. We also did not evaluate larval survival 
after ATRA/m4PTB co-treatment. For example, Chiba et al. saw no change in RA target gene 
expression after 1mg/kg ATRA in uninjured mice, yet they observed significant activation after 
AKI and ATRA treatment at the same dose, over levels induced by injury alone221. These studies 
should be performed in the context of injury before concluding definitively that m4PTB does not 
enhance recovery in zebrafish AKI through enhancing RA signaling. 
 What our data suggest is that RA signaling is required possibly upstream of m4PTB 
action. Heat shock induction of DN-RARα in zebrafish larvae blocked m4PTB’s ability to 
stimulate RTEC proliferation. This effect was more pronounced in uninjured fish. In fact in gent-
AKI fish, heat shock slightly increased RTEC proliferation in DMSO controls, although this 
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change was not significant. However, confounding factors may explain this observation, since 
heat shock has been shown to alter aspects of the injury environment including leukocyte 
migration253. Therefore, we are currently repeating these experiments in a chemical model using 
co-treatments with Ro41-5253 and m4PTB. Ultimately, m4PTB likely affects multiple pathways, 
and thorough understanding of how m4PTB mediates renal recovery will depend on a more 
global evaluation of m4PTB’s HDAC and gene targets.  
 
 
Material modified and re-published with permission: 
221*Chiba, T, *Skrypnyk, NI, *Skvarca, LB, Penchev, R, Zhang, KX, Rochon, ER, Fall, JL, 
Paueksakon, P, Yang, H, Alford, CE, Roman, BL, Zhang, MZ, Harris, RC, Hukriede, 
NA, de Caestecker, MP: Retinoic acid signaling coordinates macrophage-dependent 
injury and repair after AKI. Journal of the American Society of Nephrology : JASN, In 
press, 2015. 
*Equally contributing authors. 
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5.0  GENERAL DISCUSSION 
Collectively, these studies demonstrate the utility of gentamicin-induced AKI in zebrafish larvae 
as a tool for elucidating regenerative mechanisms in the kidney and contribute several insights to 
the AKI field. We show that the pronephric kidney in zebrafish expresses Kim1 and experiences 
leukocyte invasion after gentamicin injection, bolstering the case for conserved injury 
mechanisms between zebrafish and mammals. Together with the de Caestecker lab, we also 
show that the RA pathway mediates regenerative responses in RTECs that are critical for renal 
recovery in both zebrafish and mice221.  
  Most significantly, this work defines a paradigm for AKI drug discovery in which the 
zebrafish plays a prominent role. PTBA-class HDACi were initially identified in zebrafish 
embryos due to effects during kidney organogenesis204. These effects translated to enhanced AKI 
recovery in zebrafish larvae by increasing dedifferentiation and proliferation of RTECs. In 
mouse AKI models, these compounds promote cell cycle progression, decrease inflammatory 
M1 macrophages, and mitigate fibrosis215, 236. The translational nature of these findings justifies 
future studies in zebrafish to identify additional compounds and characterize their mechanisms in 
order to enhance the supply of new AKI treatments in the pipeline.  
 Of course, the ultimate goal is to develop effective treatments that can be used to treat 
patients who experience AKI. Despite our collaborators’ elegant work in mice, several 
fundamental questions remain before these compounds are ready for human clinical trials. 
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Importantly, we have yet to identify the molecular target – or more likely, targets – of PTBA-
class HDACi. Determining the isoform selectivity of these compounds will at least decrease the 
size of the proverbial haystack in which we must search for the pathways and genes they affect. 
In cancer cell lines, treatment with broad-spectrum HDACi alters the expression of 8-10% of all 
genes, a statistic that poignantly demonstrates the daunting nature of this task254. In the Hukriede 
lab, HDAC selectivity assays have shown that PTBA exhibits class I specificity. The most likely 
target appears to be HDAC8, the least-characterized family member in its class. Interestingly in 
terms of relevance to this work, genetic deletion of HDAC8 results in severe developmental 
cranial defects in mice and in a 46-fold induction of Lhx1 expression255. The effects of HDAC8 
repression on Lhx1 were corroborated in vitro with the development of an HDAC8-specific 
inhibitor256. Since solubility issues have so far prohibited the use of these compounds in our 
zebrafish studies, the Hukriede lab is in the process of obtaining zebrafish HDAC8 mutant lines. 
Whether PTBA directly stimulates RTEC dedifferentiation in the context of AKI through 
repression of HDAC8 represents an exciting avenue of study.   
Further, HDAC8 has been specifically linked to RA signaling. In neuroblastoma cells, 
co-treatment with ATRA and an HDAC8 inhibitor enhances tumor cell death, possibly through 
synergistic effects on CREB-mediated Caspase-8 activity201. This study shows a potential link 
between HDAC8 and RA signaling in the context of cancer. Although we showed that it is 
unlikely that PTBA-class HDACi directly stimulate RA signaling in the zebrafish larval AKI-
model, we demonstrated that upstream RA signaling is required. In the end, RA is simply one 
pathway that may be affected by PTBA treatment. Full characterization of PTBA’s effects will 
require RNA-seq studies to analyze changes in the transcriptional profile.  
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 These efforts are crucial not only to determine therapeutic mechanisms, but also to 
predict toxicity. In mouse, solubility rather than toxicity determines the maximum deliverable 
m4PTB dose (direct communication, M. de Caestecker). More generally, side effects of other 
HDACi include fatigue, nausea/vomiting, QT prolongation, and thrombocytopenia. Some 
negative effects may be due to direct cellular toxicity. In the kidney, SAHA was shown to induce 
apoptosis in 35% of rat PT cells in vitro257. In cultured mouse PT cells, TSA treatment 
upregulates the mitochondrial adapter protein p66sch. This increase is presumably linked to ROS 
generation, since knockdown of p66sch attenuates ROS production in treated cells258. In general, 
hydroxamic acids, such as SAHA and TSA, are subject to modification via sulfation, which leads 
to the buildup of highly reactive, toxic sulfate metabolites of the hydroxyl group259. For this 
reason, the therapeutic potential of hydroxamic acids may be limited, even though they are 
widely used for research purposes. Based on these studies, it may be warranted to monitor renal 
function in patients undergoing HDACi therapy, particularly if the treatment regimen involves 
those classes found to have cytotoxic effects. 
One hypothesis for decreasing these toxicities includes the use of isoform-specific 
HDACi rather than pan inhibitors like SAHA and romidepsin102.  To make this feasible, a high-
throughput assay capable of testing the isoform selectivity of novel compounds is necessary. 
Bradner et al. have developed an elegant kinetic assay for HDACs 1 through 9, which has been 
validated by profiling 20 known HDACi currently used in either research or clinical settings114. 
This provides both researchers and clinicians with valuable information about the precise 
isoform selectivity of compounds so that mechanistic and off-target effects can be evaluated. If 
PTBA is truly specific to HDAC8 alone, this is promising in terms of limiting toxicities due to 
off-target effects.  
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Finally, the best candidate must be developed to clinical trials. Over 250 analogues have 
been generated in the PTBA class, some of which surpass m4PTB’s effects on AKI recovery in 
both zebrafish and mice. Liver microsome studies, however, show that these analogues are 
rapidly metabolized, forming the PTBA parent compound that ultimately mediates their activity. 
Since metabolism differs from person to person, these prodrugs are second tier candidates for 
human therapies. In collaboration with Donna Huryn at the University of Pittsburgh Chemical 
Diversity Center, the Hukriede lab is now testing the next generation of PTBA analogues, 
designed as bioisosteres that are as stable as the parent compound, thus not requiring a prodrug 
for delivery. These ongoing studies will characterize molecular targets, toxicity, and metabolism 
and will determine whether future physicians will reach for PTBA-class HDACi as first-line 
therapy for their patients suffering from AKI. 
 
 
Material modified and re-published with permission: 
126*Brilli LL, *Swanhart LM, de Caestecker MP, Hukriede NA. HDAC inhibitors in kidney 
development and disease. Pediatric nephrology. 2013;28(10):1909-21. doi: 
10.1007/s00467-012-2320-8. PubMed PMID: 23052657; PubMed Central PMCID: 
PMC3751322. 
*Denotes equally contributing authors. 
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APPENDIX A 
SUPPLEMENTAL FIGURES 
 
Figure 31: Anatomic orientation on transverse sections of zebrafish larvae. 
(A-B) Sketch of lateral and dorsal views of zebrafish larvae. Pronephric tubules are colored in red. The black lines 
indicate the plane of section captured for immunofluorescence studies. Sketches drawn by C. Cosentino. (C-D) 
Transverse cryosection of uninjured Tg(PT:EGFP) zebrafish larvae at 5 dpf, stained with anti-GFP to mark 
pronephric tubules (green), and DAPI to mark nuclei (blue). Panel D shows the same image, with anatomic 
structures encircled and labeled for general orientation. White box shows the cropped region generally shown in 
figure panels throughout this document. Scale bars, 50 μm. 
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 Figure 32: Fluorescence western raw images. 
Unmodified fluorescent western blot images for Figure 28 (A-C) and Figure 29 (D-F). DN-RARα protein was 
detected using anti-RARα antibody (red, panels A and D), and anti-α-tubulin was used as a loading control (green, 
panels B and E). Merged images shown in panels C and F. Precision Plus Dual Color Protein Standard (Biorad) 
shows auto-fluorescence of the protein ladder visible in the red channel.   
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APPENDIX B 
SUPPLEMENTAL TABLES 
Table 1: Histology summary of antibodies and conditions. 
 
 
 
Table 2: qRT-PCR primer sequences. 
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 Table 3: Raw qRT-PCR data for zebrafish studies. 
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